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Abstract 
Cardiac lipotoxicity may induce cardiomyocyte apoptosis, eventually leading to myocardial 
dysfunction and heart failure. This study investigated whether and how junctophilin-2 (JPH2) 
plays a role in palmitate-induced apoptosis in cardiomyocytes. Here, we found palmitate 
incubation reduced JPH2 protein levels, increased cytosolic Ca2+ and induced apoptosis in 
cardiomyocytes. JPH2 over-expression prevented the increased cytosolic Ca2+ and apoptosis 
in palmitate-stimulated cardiomyocytes. JPH2 over-expression also attenuated palmitate-
induced CCAAT-enhancer-binding protein homologous protein (CHOP) expression and 
CHOP deletion alleviated palmitate-induced apoptosis. Furthermore, blocking Ca2+ release 
from ryanodine receptor-2 (RyR2) prevented palmitate-stimulated CHOP induction and 
apoptosis. Additionally, JPH2 silencing elevated cytosolic Ca2+, induced CHOP expression 
and apoptosis in cardiomyocytes; these effects of JPH2 silencing were inhibited by blocking 
Ca2+ release from RyR2. In summary, we demonstrate that JPH2 attenuates palmitate-induced 
apoptosis by reducing Ca2+ release from RyR2 and preventing CHOP expression in 
cardiomyocytes. Thus, targeting JPH2 may represent a new therapeutic strategy to treat cardiac 
lipotoxicity. 
 
Keywords: Cardiomyocyte; Junctophilin-2; Palmitate; Apoptosis; Ca2+; CHOP; 
Ryanodine receptor-2; Cardiac lipotoxicity.  
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Summary for Lay Audience 
The heart has both the greatest caloric needs and the most robust consumption of fatty acids 
of the human organs. Under certain abnormal or disease conditions, heart muscle cells get 
more fatty acids than they need and thus, the heart accumulates lipids. Excess lipids can 
directly damage heart muscle cell structures, resulting in the heart not working properly, a 
condition described as "cardiac lipotoxicity". Two human metabolic disorders are caused by 
excess lipid accumulation in heart muscle cells: obesity-related heart muscle disease in 
association with sudden heart death, and diabetic heart disease. The outcomes of cardiac 
lipotoxicity include severe heart impairment leading to death or needing replacement of the 
heart. Since type-2 diabetes and obesity are very common, cardiac lipotoxicity represents a 
major public health concern. However, effective treatments are limited for patients, which 
represents a major gap in patient care. Thus, further researches are urgently needed to better 
understand this disease, identify new targets for treatment and develop effective treatment 
modalities. 
The objective of this study was to understand how a protein called "junctophilin-2" is 
involved in cardiac lipotoxicity. Since the levels of this junctophilin-2 protein are reduced 
in heart muscle cells during lipotoxicity, we examined whether addition of junctophilin-2 
reduces heart muscle cell death caused by palmitate, a toxic lipid that has been widely 
applied in the study of cardiac lipotoxicity. It is well known that junctophilin-2 is important in 
maintaining a structure within cells which delivers ions (e.g. calcium) signals to force-generating 
fibers in heart muscle cells, leading to contraction. We examined how junctophilin-2 
normalizes calcium signals and inhibits the occurrence of a condition called "endoplasmic 
reticulum stress", which causes heart muscle cell death under over-supply of palmitate. Thus, 
this study will identify new targets for treatment. 
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Chapter 1  
1 Introduction 
1.1 Cardiac lipotoxicity 
Fatty acids (FAs) are the primary lipids used by the heart for energy production. The heart 
balances uptake, oxidation and metabolism of FAs to maintain ATP production, lipid 
signaling and membrane biosynthesis (1). Diabetes and obesity are prevalent in western 
countries. In both conditions, cardiomyocytes take up excessive fatty acids which may alter 
the structures of cells and activate downstream pathways, leading to cardiomyocyte 
apoptotic cell death followed by myocardial dysfunction, a condition described as cardiac 
lipotoxicity (2). This will eventually lead to adverse myocardial remodeling and heart 
failure (3). However, it remains incompletely understood how the excessive lipids cause 
cardiac dysfunction and heart failure. 
The healthy adult heart acquires 60–80% of its energy requirements by mitochondrial β-
oxidation of fatty acids and 20–30% of its energy requirements from glucose. In addition, 
ketone bodies, lactate and amino acids are also utilized for energy production (4, 5). 
Normally, the origin of fatty acids supplied to the heart is either plasma fatty acids bound 
to albumin or fatty acids contained within chylomicron- or very-low density lipoprotein 
(VLDL)-triacylglycerol (TAG). Free fatty acids are released by lipoprotein lipase (LPL) 
from chylomicron- or VLDL-TAG and then transported into the cardiomyocytes by 
diffusion or via protein-mediated uptake. The proteins which mediate free fatty acids 
uptake involve the cluster of differentiation 36 (CD36), fatty acid transport protein (FATP) 
and plasma membrane fatty acid binding protein (FABPpm). In the process of protein-
mediated fatty acid uptake, the fatty acids are initially bound to FABPpm, and then 
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transported via FAT/ CD36 or FATP1/6. After transporting into the cytosol, the fatty acids 
are used for ATP production by mitochondrial β-oxidation, participate in anabolic 
metabolism into the endogenous TAG pool, or contribute to membrane synthesis through 
the production of  phospholipid (6).  
The healthy heart is very flexible in its regulation of overall energy metabolism. However, 
the balance between energy demand and supply is disturbed under pathological conditions. 
For example, the increase of fatty acid supply and the subsequent increase of fatty acid 
uptake induce the lipid accumulation in the heart (7). It is also postulated that mitochondrial 
dysfunction results in lipid accumulation in the heart by impairing fatty acid β-oxidation 
(8-10). Excessive lipid accumulation in the heart induces cardiac lipotoxicity which is 
associated with insulin resistance, cardiomyocyte apoptosis and subsequent cardiac 
dysfunction (4, 11). As described above, excessive fatty acids accumulated in the 
cardiomyocytes have several fates.  The excessive fatty acids may undergo β-oxidation in 
the mitochondria for energy metabolism or be stored as TAG (4, 7). However, when the 
capacity for mitochondrial β-oxidation of fatty acids cannot keep up with the excessive 
uptake of fatty acids, lipid intermediates will accumulate, including TAG, diacylglycerols 
(DAGs), ceramides, long-chain acyl CoAs, and acylcarnitines (4, 12, 13). The 
accumulation of these toxic lipid intermediates may result in mitochondrial dysfunction 
(14, 15), insulin resistance (16-19), cellular apoptosis (20, 21) and ventricular dysfunction 
(22-24). 
Palmitate (PA) is the most common saturated fatty acid found in western diets (25). 
According to the World Health Organization, consumption of palmitate increases the risk 
of developing cardiovascular diseases (26). Palmitate, a saturated fatty acid, has been 
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widely used in the study of cardiac lipotoxicity. Palmitate-treated neonatal rat 
cardiomyocytes have elevated reactive oxygen species (ROS) and changes in 
mitochondrial morphology which are accompanied by the loss of mitochondrial reticulum, 
suggesting increased mitochondrial fission (27). The level of mitochondrial ROS correlates 
with mitochondrial dysfunction and apoptosis in cardiomyocytes induced by palmitate (27, 
28). Palmitate treatment can also result in down-regulation of peroxisome proliferator-
activated receptors (PPARs), which in turn, impair the expression of important proteins 
involved in mitochondrial β-oxidation (29). Nevertheless, the molecular mechanisms by 
which palmitate induces mitochondrial dysfunction and cell death have not been fully 
addressed. 
1.2 Junctophilin-2 
Junctophilin-2 (JPH2) is encoded by the JPH2 gene which was discovered about 2 decades 
ago (30). There are 4 members in the junctophilin protein family (JPH1-4). They bridge 
the physical gap between the plasma membrane and the sarcoplasmic/endoplasmic 
reticulum (SR/ER) in excitable cells (31). JPH2 is the main junctophilin isoform in the 
heart, although JPH1 is also expressed to a lesser extent (30). JPH1 is the major isoform in 
skeletal muscle and JPH3 and JPH4 are neuronal isoforms found in brain (32).  
Junctophilins are highly conserved molecules. There are 4 different components of JPH2 
(33) (Figure 1). The 8 ‘membrane occupation and recognition nexus’ (MORN) motifs 
(~330 amino acids) in the N-terminal region are thought to mediate attachment to the 
plasma membrane. The MORN motif region is followed by a well-conserved α-helical 
domain (~100 amino acids) which serves as the structural basis for the maintenance of a 
uniform distance between the plasma membrane and the SR/ER. There is also a putative 
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divergent region which exhibits a high degree of conservation (83%−91%) across species, 
but shows poor conservation across the 4 JPH isoforms (15%−17%). The function of this 
domain is not clear presently, but it may be associated with isoform-specific JPH functions. 
Finally, JPH2 binds to the ER/SR membrane by a C-terminal, 22-amino acid 
transmembrane anchor (30). 
JPH2 is a membrane-binding protein that maintains a fixed distance between the plasma 
membrane and the SR/ER, which plays an important role for proper Ca2+-induced Ca2+ 
release during the excitation-contraction process (31). Also, JPH2 is essential for the 
development of postnatal T-tubules in mammals (34, 35). It can also maintain the 
architecture of the junctional membrane complexes (JMCs) and stabilize local ion channels 
in mature cardiomyocytes (36). A recent study also shows that JPH2 can stabilize the 
activity of ryanodine receptor 2 (RyR2) in cardiomyocytes (36). Interestingly, it is recently 
found that JPH2 can be cleaved by the Ca2+ dependent protease, calpain under stress and 
the liberated N-terminal fragment of JPH2 (JP2NT) can serve as a transcription regulator, 
inducing cardioprotective transcriptional reprogramming (37). All of these prior findings 
underscore an important role of JPH2 in cardiac pathophysiology. In line with this, JPH2 
dysfunction of mutations or down-regulation has been associated with hypertrophic 
cardiomyopathy, arrhythmias, and heart failure (35).  
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Figure 1: JPH2 structure and Ca2+ cycling in cardiomyocytes. 
JPH2 is composed of the N-terminal MORN motifs, alpha helix region, divergent region 
and transmembrane domain. In cardiomyocytes, the entry of a small amount of Ca2+ via 
VGCC triggers the opening of RyR2 and the release of a large amount of Ca2+ from the SR, 
a process described as Ca2+-induced Ca2+ release or Ca2+ coupling. The ensuing increase of 
cytoplasmic Ca2+ enables contraction. Finally, Ca2+ is removed from the cytoplasm back 
into the SR by SERCA pump and out of the cell by NCX. JPH2: junctophilin-2; VGCC: 
voltage-gated Ca2+ channel; RyR2: ryanodine receptor-2; SERCA: sarco/endoplasmic 
reticulum Ca2+ ATPase pump; NCX: Na+/Ca2+ exchanger; PM: plasma membrane; SR: 
sarcoplasmic reticulum; MORN: membrane occupation and recognition nexus; TMD: 
transmembrane domain. 
1.2.1 JPH2 in T-tubule maturation 
Knockdown of JPH2 by cardiac-specific short hairpin RNA (shRNA) in mice destroys the 
formation of mature T-tubules within the first few weeks of life (35). Conversely, the 
maturation of T-tubules occurs earlier in mice over-expressing JPH2 (35). This study 
suggests that JPH2 is highly involved in the development of T-tubules to induce membrane 
invagination. T-tubule architecture has been reported to be pathologically remodeled in 
both patients and animal models with failing hearts (38). A high rate of mortality with rapid 
development of systolic heart failure is found in mice with acute conditional cardiac 
  
6 
shRNA-mediated knockdown of JPH2 (39). Similarly, JPH2 expression is decreased in the 
myocardial ischemia model with loss of colocalization of JPH2 and RyR2 (40). While the 
loss of JPH2 has yet to be studied in patients with more diverse cardiac disease etiologies, 
the disruption of T-tubule architecture which occurs in ischemic heart disease, idiopathic 
dilated cardiomyopathy, and hypertrophic cardiomyopathy (HCM) is likely a very early 
event in failing hearts (34, 41, 42).  
1.2.2 JPH2 in the postnatal development of junctional membrane complexes 
(JMCs) 
JPH2 can anchor T-tubules and SR. JPH2 null mice are embryonically lethal by Day E10.5 
when the heart normally initiates contractile function, demonstrating the important 
function of JPH2 (30). There is an extensive loss of JMCs in the JPH2 null mice in 
association with spontaneous SR Ca2+ release and irregular Ca2+ transients, indicating that 
JPH2 is very important in the postnatal development of JMCs (36). Cardiac-
specific JPH2 knockdown reduces the number of JMCs, increases the variability of the 
distance between the plasma membrane and the SR/ER and results in impaired cardiac 
contractility, leading to heart failure and increased mortality (39). JPH2 deficiency affects 
T-tubule elements preferentially, suggesting that longitudinal tubule elements may be 
JPH2 independent, which is correlated with changes in T-tubule structure and JPH2 down-
regulation in heart failure (43). 
1.2.3 JPH2-mediated regulation of RyR2 
While the importance of JPH2 for T-tubule function has received significant attention, T-
tubule independent functions of JPH2 in cardiomyocytes have just been recognized. 
Decreased or dysfunctional JPH2 results in RyR2 dysfunction in cardiomyocytes, 
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indicating a novel role of JPH2 in maintaining RyR2 stability, which is independent of the 
T-tubule system (35). Studies using mice with a JPH2 missense mutation (JPH2-E169K) 
reveal that dysfunctional JPH2 disrupts the interaction between RyR2 and JPH2 and thus 
leads to Ca2+ leak from RyR2  (37, 44). This results in an increase in diastolic Ca2+ and 
promotes the activation of sarcolemmal Na+-Ca2+ exchanger (NCX), thereby creating a net 
depolarizing current, leading to delayed afterdepolarizations (DADs), an important 
mechanism contributing to atrial arrhythmias (45-47). Therefore, arrhythmogenic SR 
Ca2+ leak may be initiated by the loss of the stabilizing interaction between JPH2 and RyR2. 
However, the molecular mechanisms by which JPH2 stabilizes RyR2 remain unknown. 
Given the importance of Ca2+ cycling in cardiac bio-pathology, this novel function of JPH2 
may be important in maintaining cardiac normality, suggesting that a reduction and/or 
dysfunction of JPH2 may play a role in cardiac injury under stress. 
1.2.4 Regulation of JPH2 in cardiomyocytes 
JPH2 down-regulation has been involved in various cardiac diseases and some mechanisms 
have been suggested to explain the loss of JPH2 (Figure 2). It is shown that JPH2 is the 
target of microRNA 24 (miR-24), which may be responsible for decreased JPH2 in cardiac 
hypertrophy (48). In failing hearts, miR-24 is up-regulated (48, 49), and is associated with 
the down-regulation of JPH2 (48, 50). Silencing miR-24 prevents the development of heart 
failure which is said to be due to maintaining the expression of JPH2 and T-tubule integrity 
(51), confirming the relationship between miR-24 and JPH2. Another study finds that JPH2 
is the target of miR-34a. Initial cardiac defects diminish RBFox2 (RNA binding protein) 
expression, which induces the expression of miR-34a, and elevated miR-34a targets JPH2 
to down-regulate JPH2 expression, which further results in heart dysfunction, leading to 
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progressive heart failure. The administration of a miR-34a mimic is sufficient to induce 
cardiac defects. However, antagonism of miR-34a alleviates RBFox2 depletion-induced 
heart dysfunction (52).  
JPH2 down-regulation has also been attributed to cleavage by calpain in failing hearts (53). 
Calpain is a protease that is activated by elevated intracellular Ca2+ (54, 55). Activation of 
the heterotrimeric G protein Gαq can activate calpain. Loss of T-tubule integrity, together 
with a pronounced decrease in full-length JPH2 are found in a transgenic mouse with 
inducible activation of the heterotrimeric G protein Gαq. Calpain inhibitors prevent Gαq-
mediated JPH2 down-regulation, suggesting calpain is responsible for generation of the 
JPH2 cleavage fragments (53). Furthermore, decreased full-length JPH2 level is found in 
ischemia-reperfusion injury, though no cleavage fragment is detected (56).  
 A most recent study shows that JPH2 is also a target of matrix metalloproteinase-2 (MMP2) 
in myocardial ischemia-reperfusion (IR) injury (57). MMP2 is a Zn2+ and Ca2+-dependent 
protease that is activated by oxidative stress in myocardial IR injury which cleaves both 
intracellular and extracellular substrates. IR injury increases the degradation of JPH2 and 
impairs the recovery of cardiac contractile function. ARP 100, a MMP inhibitor, attenuates 
JPH2 proteolysis and improves the recovery of cardiac contractile function in IR hearts. In 
addition, MMP2 is co-localized with JPH2 in IR hearts. It is confirmed that JPH2 is 
susceptible to proteolysis by MMP2 and multiple cleavage sites have been predicted (57).  
In addition to its down-regulation, loss of normal subcellular localization of JPH2 due to 
microtubule polymerization also contributes to JPH2 dysregulation (58). Microtubule 
densification, defined as the increase in microtubule density due to enhanced microtubule 
polymerization, is commonly found in human failing hearts and mouse models of heart 
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failure (56, 59). Zhang et al. observed that the subcellular distribution of JPH2 is linked to 
microtubule dynamics (58). Under cardiac stress, redistribution of JPH2, resulting from the 
densification of the microtubule network, induces T-tubule remodeling and excitation-
contraction coupling dysfunction, contributing to the development of heart failure (58).    
 
Figure 2: Mechanisms of JPH2 dysregulation in heart diseases. 
Depicted are miRNA-mediated gene silencing by miR-24 and miR-34, calpain-mediated 
proteolysis, MMP2-mediated proteolysis, and redistribution to the cell periphery in 
response to microtubule polymerization. JPH2: junctophilin-2; VGCC: voltage-gated Ca2+ 
channel; RyR2: ryanodine receptor-2; miR: micro RNA; MMP2: matrix metalloproteinase-
2; PM: plasma membrane; SR: sarcoplasmic  reticulum. 
 
1.2.5 JPH2 encodes transcription regulator under stress 
JPH2 is required for normal E-C coupling. After cardiac stress, Ca2+ overload induces 
protease calpain activation. JPH2 is cleaved by calpain and liberates the N-terminal 
fragment (JP2NT), disrupting the ultrastructure of the E-C coupling machinery. JP2NT 
translocates to the nucleus via a conserved nuclear localization signal, binds to the TATA 
box of genomic DNA via the alanine-rich region and associates with a MEF2 response 
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element to repress the transcription of genes that control deleterious cardiac remodeling 
(37). Transgenic over-expression of JP2NT in mice results in attenuated pathological 
remodeling in response to cardiac stress. Conversely, loss of nuclear JP2NT function 
accelerates stress-induced development of hypertrophy and heart failure in mutant mice 
(37). This finding reveals that cardiomyocytes possess a self-protective mechanism in 
failing cardiomyocytes that transduces mechanical information (E-C uncoupling) into 
transcriptional reprogramming in the stressed heart (37). 
1.3 Endoplasmic reticulum stress 
The endoplasmic reticulum (ER) is a multifunctional intracellular organelle supporting 
many processes required by almost every mammalian cell, including cardiomyocytes. It 
performs diverse functions, including protein synthesis, translocation across the membrane, 
integration into the membrane, folding and posttranslational modification (60). Also, the 
ER participates in the synthesis of phospholipids and steroids on the cytoplasmic side of 
the ER membrane (61). It is also the major intracellular Ca2+ reservoir in the cell and plays 
an important role in the regulation of Ca2+ homeostasis in cardiomyocytes (62, 63).  
ER stress is a condition that is accelerated by the accumulation of unfolded/misfolded 
proteins after the disturbance in ER quality control in a variety of physiological and 
pathological conditions (64). Upon ER stress, cells activate a series of complementary 
adaptive mechanisms to cope with protein-folding alterations, which together are known 
as the unfolded protein response (UPR) (63). The UPR transduces information about the 
protein-folding status in the ER lumen to the nucleus and cytosol to buffer fluctuations in 
unfolded/misfolded protein load (65, 66). When cells undergo irreversible ER stress, this 
pathway eliminates damaged cells by apoptosis (67). ER stress is found to be involved in 
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many cardiovascular diseases, such as ischemic heart disease, atherosclerosis, cardiac 
hypertrophy, cardiac lipotoxicity, heart failure etc. (68). 
1.3.1 Unfolded protein response (UPR) 
UPR is a defense mechanism which removes the unfolded/misfolded proteins and prevents 
their accumulation. The UPR is activated by 3 main transmembrane stress sensors, 
including inositol-requiring protein 1 α (IRE1α), protein kinase RNA-like ER kinase 
(PERK) and activating transcription factor 6 (ATF6) and results in a lot of cellular 
responses (63, 68).  
In the IRE1α pathway, IRE1α dimerization triggers the activation of its RNase, which 
promotes the mRNA encoding unspliced X box-binding protein 1 (XBP1) and produces a 
transcription factor, spliced XBP1 (XBP1s). XBP1s regulates the transcription of genes 
which encode proteins involved in protein folding, protein quality control, phospholipid 
synthesis and ER-associated degradation (ERAD). IRE1α can degrade some mRNAs 
through regulated IRE1-dependent decay (RIDD). IRE1α can also trigger ‘alarm stress 
pathways’, including those driven by nuclear factor-κ B (NF-κ B) and JUN N-terminal 
kinase (JNK) (63, 69).  
In the PERK pathway, PERK activation can phosphorylate the initiation factor eukaryotic 
translation initiator factor 2α (eIF2α) to prevent the synthesis of general protein. PERK 
activation can also phosphorylate the nuclear factor erythroid 2-related factor 2 (NRF2) 
which is a transcription factor controlling redox metabolism. eIF2α phosphorylation allows 
the translation of the transcription factor ATF4, which regulates the transcription of genes 
participating in apoptosis, autophagy, antioxidant responses and amino acid metabolism. 
(63, 70).   
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In the ATF6 pathway, there is a basic Leu zipper (bZIP) transcription factor in the cytosolic 
domain of ATF6  and it is localized to the ER. When cells undergo ER stress, ATF6 can 
be transported to the Golgi apparatus by interacting with the coat protein II (COPII) 
complex. Then, ATF6 is processed by site 1 protease (S1P) and S2P and its cytosolic 
domain fragment (ATF6f) is released. ATF6f regulates the up-regulation of genes encoding 
XBP1 and ERAD components (63, 71).  
These 3 branches of ER transmembrane sensors can trigger adaptive responses through the 
splicing of XBP1, the phosphorylation of eIF2α and the translation of transcription factor 
ATF4. Finally, the unfolded protein response related genes are induced, including 
CCAAT-enhancer-binding protein (C/EBP) homologous protein (CHOP), chaperones 
glucose-regulated protein-78 (GRP78), GRP94 etc (2). 
1.3.2 Calcium homeostasis and ER stress 
As described above, ER stress is induced by the accumulation of unfolded/misfolded 
proteins. It is shown that oxidative stress, ischemia, disturbance of Ca2+ homeostasis and 
high-fat diet are related to the induction of ER stress (2, 72-74).   
In cardiomyocytes, sarcoplasmic/endoplasmic reticulum (SR/ER) is the major intracellular 
Ca2+ reservoir. The entry of a small amount of Ca2+ through L-type Ca2+ channels on 
plasma membrane during an action potential triggers the synchronized opening of RyR2 
on the SR which allows a rapid and transient release of Ca2+ from the SR. This process is 
described as Ca2+-induced Ca2+ release (CICR) or Ca2+ coupling. The subsequent elevation 
of intracellular Ca2+ promotes the contraction of cardiomyocytes. Finally, Ca2+ is removed 
from the cytoplasm back into the SR by sarcoplasmic/endoplasmic reticulum ATPase 
(SERCA2a) pump and out of the cell by Na+-Ca2+ exchanger (NCX) (Figure 1) (75). 
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Ca2+ homeostasis refers to the regulation of Ca2+ concentration in the body. This 
concentration is tightly controlled by a stabilizing system consisting of Ca2+ channels and 
Ca2+ buffering proteins (76). Ca2+ homeostasis is crucial for cell survival. The disruption 
of Ca2+ homeostasis induces ER stress and leads to the apoptotic cell death (76). 
Reticulocalbin 1 (RCN1), a target of NF-κB, suppresses ER Ca2+ release by binding to 
inositol 1,4,5-trisphosphate receptor type 1 (IP3R1) and decreases the UPR, thereby 
inhibiting ER stress-induced apoptosis (77). The Ca2+ channel RyRs are involved in ER 
stress and β-cell death (78). In this study, ER stress following SERCA inhibition is 
attenuated by blocking RyRs. Conversely, stimulation of RyRs accelerates thapsigargin-
induced ER depletion and apoptosis (78).  
1.3.3 ER stress and apoptosis 
If ER stress is prolonged or overwhelming, it can induce apoptotic cell death through 
CHOP and/or other pathways (79). 
CHOP, also known as growth arrest- and DNA damage-inducible gene 153 (GADD153), 
is a 29 kDa protein with 169 (human) or 168 (rodents) amino-acid residues. It is composed 
of 2 known functional domains, an N-terminal transcriptional activation domain and a C-
terminal basic-leucine zipper (bZIP) domain (80). CHOP is ubiquitously expressed at very 
low levels and is present in the cytosol under nonstressed conditions. However, ER stress 
can induce the expression of CHOP and lead to its accumulation in the nucleus (81). CHOP 
works as a transcription factor that regulates genes involved in apoptotic cell death (82, 
83). 
CHOP is the main up-regulated pro-apoptotic player during excessive ER stress (84). The 
transcriptional induction of CHOP is controlled by the PERK–ATF4 axis in a positive 
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manner (79) and this up-regulation switches the consequences of the UPR from 
proadaptive to proapoptotic signaling. In addition to the inhibition of Bcl-2, over-
expression of CHOP promotes several mechanisms of apoptosis including the stimulation 
of caspase activity (85) and Bax translocation from cytosol to mitochondria (86). 
Knockdown of CHOP reduces ER stress-mediated apoptosis (82) and over-expression of 
CHOP triggers apoptosis after treatment with ER stress inducers (85).  
1.3.4 ER stress in cardiovascular diseases 
Recent animal and human studies have demonstrated that ER stress is implicated in the 
pathophysiology of various cardiovascular diseases (83, 87). In ischemic heart disease, cell 
death is reduced in cardiomyocytes after the inhibition of ER stress and silencing of the 
IRE1 gene (88). In addition, the ER may induce apoptotic signaling by increasing the 
expression of CHOP involved in the transition from cardiac hypertrophy to heart failure 
(83). In atherosclerosis, the intensity of ER stress increases and the PERK pathway induces 
cell death by activating IRE1α and inducing apoptosis signaling pathways (87).  
Notably, ER stress is induced and has been implicated in cardiac lipotoxicity. Our previous 
work found that in high fat diet fed mouse hearts, ER stress was induced and apoptosis was 
increased. In addition, palmitate also induced ER stress and apoptotic cell death compared 
to oleate in cultured cardiomyocytes (2). These results mean that ER stress is induced and 
detrimental under cardiac lipotoxicity condition. However, sequestration of fatty acids in 
triglycerides can prevent ER stress in an in vitro model of cardiomyocyte lipotoxicity (89).  
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1.4 Apoptosis in cardiomyocytes 
1.4.1 Apoptosis: programmed cell death 
Apoptosis is widely known as programmed cell death which may occur in multicellular 
organisms. Apoptosis can result in characteristic cell changes and death. There are 3 classic 
signaling pathways of apoptosis, including the intrinsic (mitochondrial) pathway, the 
extrinsic (death receptor) pathway, and the ER stress pathway. 
1.4.1.1 The morphological change of apoptosis 
Apoptosis is an organized self-killing process (90). The cells begin to shrink after the 
activation of apoptotic pathways. Morphological changes include smaller cellular size, 
denser cytosol, chromatin condensation and more tightly packed organelles. Subsequently, 
apoptotic bodies are formed, where the plasma membrane encloses the tightly packed 
organelles with or without a nuclear fragment. At the same time, nuclear proteins and 
cytoskeletal proteins are cleaved and degraded by caspases in the execution phase of 
apoptosis (91). Finally, macrophages will phagocytose the apoptotic bodies through 
binding to the externalized phosphatidylserine, which is located on the outer leaflet of the 
bilayer (92).  
Many cellular killing and engulfment proteins are involved in the apoptotic process, among 
which caspases play very important roles. Once the apoptotic pathways are initiated, the 
activated caspases will activate other procaspases, promoting the protease cascade and then 
amplifying the apoptotic signal irreversibly (93). Recently, more than 10 caspases have 
been found and recognized during the apoptotic process, including the initiators (caspase-
2,-8,-9,-10), the executioners (caspase-3,-6,-7) and other regulators (caspase-11,-12,-13,-
14) (91, 94).  
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1.4.1.2 The extrinsic pathway  
The extrinsic pathway is triggered by transmembrane death receptors which belong to 
tumor necrosis factor (TNF) receptor family and contain a death domain. Several classical 
ligands and their corresponding death receptors are apoptosis-stimulating fragment ligand 
(FasL)/FasR, and TNF-α/TNFR1. TNF-related apoptosis-inducing ligand (TRAIL)/DR4 
and TRAIL/DR5 will transmit the death signals from cell surface to intracellular pathways 
through the death domain. For example, after the binding of FasL to FasR or TNF-α to 
TNFR1, the fas-associated death domain (FADD) will be recruited and bound to the ligand-
receptor complex (95). Subsequently, FADD will activate procaspase-8 and form a death-
inducing signaling complex (DISC) (96). Finally, caspase-8 activated by DISC will trigger 
the activation of caspase-3 and caspase-7 and then induce the apoptotic cascade, leading to 
the execution phase of apoptosis (97).  
1.4.1.3 The intrinsic pathway 
The intrinsic pathway is mitochondrial-triggered. This pathway is usually activated by 
stimuli including hypoxia, hyperthermia and the absence of growth factors. These stimuli 
promote the opening of mitochondrial permeability transition pore (MPTP) and then 
accelerate the release of some pro-apoptotic proteins including cytochrome c (Cyt c) and 
apoptosis-inducing factor (AIF) from the mitochondrial intermembrane space into the 
cytosol (98). Cyt c will bind and activate apoptotic protease activating factor 1(Apaf-1) as 
well as procaspase-9 and then result in the activation of caspase-9, which in turn activates 
caspase-3 and caspase-7 (99, 100). However, AIF will translocate to the nucleus and induce 
chromatin condensation and DNA fragmentation in a caspase-independent way in the late 
phase of apoptosis (101).    
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Notably, intrinsic pathway-induced apoptosis is regulated by B-cell lymphoma 2 (Bcl-2) 
family proteins (102) which are in the outer membrane of mitochondria. Bcl-2 family 
proteins can control the permeability of mitochondrial membrane and participate in the 
regulation of the release of Cyt c. Bcl-2 family proteins can be classified into pro-apoptotic 
and anti-apoptotic proteins. The pro-apoptotic proteins include Bax, Bad, Bak, Bim, Bid, 
Puma and BNIP3 (103); while the anti-apoptotic proteins contain Bcl-2, Bcl-XL, Bcl-x, 
and BAG (104). Bax can be up-regulated by the tumor suppressor protein p53 in the 
nucleus or mitochondria (np53 or mp53) (100, 105). However, Bcl-2 or Bcl-xL may block 
np53 or mp53-induced apoptosis (104-106). When p53 is down-regulated, Bax and 
caspase-3 are also down-regulated in the heart (107). Interestingly, there is interaction 
between the extrinsic and intrinsic pathways. It is found that Fas-mediated apoptosis can 
also induce mitochondrial damage through the caspase-8-mediated cleavage of Bid (108).  
1.4.1.4 The ER stress pathway 
The ER stress pathway is a relatively newly described pathway contributing to the 
regulation of apoptosis. It is commonly induced under some physiological or pathological 
conditions including protein folding, disruption of intracellular Ca2+ homeostasis, hypoxia, 
oxidative stress, ischemia and lipid metabolic disorders (65, 109). Although ER stress is 
important for cell survival (65), it can also result in apoptosis under prolonged or chronic 
stimulation (110). As described before, ER stress is sensed by UPR which is activated by 
3 main stress sensors including IRE1α, PERK and ATF6 (62).   
In the IRE1α pathway, IRE1α interacts with TRAF2 (tumor necrosis factor receptor 
(TNFR)-associated factor-2) and initiates JNK expression which is demonstrated to be 
involved in cell death (111, 112). Therefore, it is assumed that JNK is associated with IRE1-
  
18 
mediated apoptosis. Notably, IRE1α can be activated through binding to Bak and Bax (113). 
Procaspase-12 is activated through interacting with IRE1α-TRAF2 complex (114). In 
addition, IRE1α may promote apoptosis by activating the RIDD pathway (79, 115); 
however, the specific mechanism is unclear. Interestingly, IRE1α can also splice and 
activate XBP1 mRNA (116) which participates in cell survival. As a result, IRE1α is a 
crucial protein and plays an important role in the regulation of apoptosis and survival under 
ER stress.  
In the PERK pathway, PERK promotes the phosphorylation of eIF2α and induces the 
translation of ATF4, which participates in proapoptotic process. ATF4 induces the 
expression of CHOP. CHOP can suppress the expression of Bcl-2 (85) and increase the 
expression of Bim, Puma and Bax (117-120). Also, CHOP can activate ER oxidase 1α 
(ERO1α) (121) and induce Ca2+-dependent apoptosis through the CHOP-ERO1α-IP3R1- 
Ca2+-CaMKII pathway (122). Caspase-12 and Bid are also reported to be involved in 
CHOP-ERO1α-IP3R- Ca2+-calpain pathway during ER stress (123, 124). Notably, CHOP- 
and IRE1α-induced apoptosis can be repressed by a phenomenon called pre-conditioning, 
where low-level ER stress can partially prevent UPR before a robust UPR activation (125).  
In the ATF6 pathway, ATF6 can activate XBP1 and exert a prosurvival effect (116). 
Conversely, inhibition of ATF6 can promote apoptosis (126). However, the detailed 
mechanism of ATF6-involved apoptosis needs further investigation.  
1.4.2 Apoptosis in cardiac lipotoxicity 
1.4.2.1 Cardiac lipid overload induces apoptosis 
Cardiac lipid overload is associated with, and thought to contribute to, the initiation of the 
apoptotic cascade. Studies, primarily in isolated cardiomyocytes, have implicated saturated 
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FAs as a primary cause of apoptosis (127). Treatment of isolated neonatal rat ventricular 
myocytes with palmitic acid can generate cytoplasmic ceramide, which activates JNK1/2 
that interacts with Bax in the mitochondrial membrane, leading to apoptosis associated 
with cardiolipin loss, cytochrome c release, mitochondrial swelling, and DNA laddering 
(127, 128). 
Accumulation of FAs has been linked to the induction of ER stress. Specifically, palmitate-
induced ER stress has been considered to be a secondary event that follows oxidative stress 
and the generation of ROS, and results in an induction of eukaryotic elongation factor (eEF) 
1A-1, which interferes with the integrity of the cytoskeleton and causes cell death (129). A 
more direct mechanism of palmitate-induced ER stress has also been proposed in the same 
study. This mechanism involves the incorporation of palmitate in phospholipid and TG 
species in microsomal membranes so that ER membrane integrity is compromised and 
protein-folding chaperones are redistributed to the cytosol (130). Another study has 
reported that the esterification of palmitate can directly cause ER fission (131). Intensive 
ER stress may result in apoptosis. 
1.4.2.2 Apoptosis induces cardiomyocyte dysfunction and cardiac 
remodeling 
Cardiac lipid overload is associated with, and thought to contribute to, the initiation of the 
apoptotic cascade. Cardiomyocyte loss via apoptosis together with pathological 
cardiomyocyte hypertrophy may produce progressive myocardial dysfunction, leading to 
heart failure (132). Cardiac hypertrophy occurs in response to long-term increases in 
hemodynamic load related to various physiological and pathological conditions. The 
hypertrophic process is characterized by structural changes at the cardiomyocyte level that 
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are translated into alterations in chamber size and geometry, collectively called remodeling 
(133, 134). Functional benefits of the hypertrophic response include an increase in the 
number of contractile elements, a lowering of wall stress through increased wall thickness 
in concentric hypertrophy, and an increase of stroke volume by increasing end-diastolic 
volume in eccentric hypertrophy (134). By contrast, pathological forms of cardiac 
hypertrophy develop in response to persistent increases in hemodynamic load. 
Epidemiological studies have demonstrated that pathological cardiac hypertrophy is a risk 
factor for future cardiac events (135, 136). Indeed, pathological cardiac hypertrophy often 
enters a phase of pathological remodeling that leads to contractile dysfunction, heart failure 
and sudden death (137).  
Cardiomyocyte loss via apoptosis also participates in cardiac fibrosis (138). Fibrosis is the 
excessive deposition of extracellular matrix (ECM), such as collagens and fibronectin, 
resulting in the excessive accumulation of fibrous connective tissue (139, 140). Fibrosis is 
an essential process in the repair of damaged tissues and wounds, but its accumulation in 
organs and tissues can lead to scarring, organ dysfunction and, ultimately, failure (138). 
Paracrine signaling from fibroblasts induces cardiomyocyte hypertrophy. Fibroblasts can 
produce a number of cytokines and growth factors, including TGF-β, interleukin-33 (IL-
33), fibroblast growth factor 2 (FGF2), tumor necrosis factor alpha (TNF-α), insulin growth 
factor (IGF1) and endothelin-1 (ET-1), which directly affect cardiomyocyte function in 
vitro and/or in vivo (141-148). Myofibroblasts express a large number of structural ECM 
proteins and matrix remodeling proteins and together determine the functionality of the 
ECM. Thus, besides the amount of ECM, the level of collagen cross-linking also strongly 
determines the development of diastolic and systolic dysfunction (137, 149-154). Fibrosis 
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also disturbs cardiac electrophysiology and induces rhythm disturbances. In mice, TGF-β 
over-expression results in atrial fibrosis, without ventricular involvement, and these mice 
develop inducible atrial fibrillation (AF) (155, 156). Finally, fibrosis limits nutrient supply 
to the myocardium by limiting cardiac function and myocardial blood flow (149). 
Perivascular fibrosis in coronary arteries reduces oxygen delivery toward myocardial tissue, 
reduces coronary reserves and promotes myocardial ischemia (137, 154). Thus, fibrosis 
impairs cardiac function by at least 3 mechanisms, including induction of myocardial 
stiffness, induction of atrial fibrillation and limiting oxygen and nutrient supply to the 
stressed myocardium. These will promote cardiomyocyte hypertrophy and heart failure. 
1.5 Rationale 
Cardiac lipotoxicity is a critical mechanism underlying cardiac complications in patients 
with obesity and/or diabetes. Cardiac lipotoxicity results from the accumulation of lipid 
intermediates in non-adipose tissue, leading to cellular dysfunction and death. However, it 
needs to be further elucidated how the accumulation of lipids causes cellular dysfunction 
and death in the heart.  
In our lab, we previously reported that palmitate treatment activated calpain and induced 
ER stress and subsequent cell injury when compared to oleate in cardiomyocytes (2). We 
further found that the protein levels of JPH2 were reduced in high fat diet-fed mouse hearts, 
which correlated with myocardial injury and dysfunction (2). These previous findings raise 
an important possibility that decreased JPH2 may play a role in mediating ER stress and 
apoptosis in cardiomyocytes during lipotoxicity and thus, up-regulation of JPH2 may 
protect cardiomyocytes against lipotoxicity. 
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Understanding the role of JPH2 in cardiac lipotoxicity is clinically relevant because the 
protein levels of JPH2 are reduced in various human diseased hearts. This study determines 
whether and how JPH2 provides a cardiac protective role in lipotoxicity. 
1.6 Hypothesis 
JPH2 will protect cardiomyocytes against palmitate-induced injury by inhibiting 
endoplasmic reticulum (ER) stress. 
1.7 Specific aims 
1.7.1 To confirm that palmitate induces cell injury in cardiomyocytes. 
1.7.2 To determine if JPH2 knockdown enhances whereas JPH2 over-
expression attenuates palmitate-induced cell injury in cardiomyocytes. 
1.7.3 To determine the mechanism by which JPH2 protects cardiomyocytes 
against palmitate-induced injury by modulating calcium release from RyR2 
and inhibiting ER stress. 
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Chapter 2  
2 Materials and Methods 
2.1 Animals 
This investigation conforms to the Guide for the Care and Use of Laboratory Animals 
published by the US National Institutes of Health (NIH Publication, 8th Edition, 2011). All 
experimental procedures were approved by the Animal Use Subcommittee at the 
University of Western, Ontario, Canada. Breeding pairs of C57BL/6 mice and C57BL/6 
background CHOP-/- mice were purchased from the Jackson Laboratory (Bar Harbor, 
Maine). Mice used in this study, including controls, were littermates.  
For genotyping of CHOP-/- mice, 1-2 mm of the tip of the tail was cut from CHOP-/- mice 
and put into a microtube (1.5mL). The DNA from CHOP-/- mice was extracted. Briefly, the 
tail was lysed in solution A (Table 1) and incubated in a metal bath at 100 °C for 45 min. 
Then, the microtube containing solution A was cooled to room temperature. The 
stabilization buffer solution B (Table 2) was added to the microtube and mixed completely. 
After that, the DNA lysate was centrifuged at 10,000g for 5 min and the supernatant was 
ready for PCR (FroggaBio). The PCR system (Table 3) and protocol (Table 4) for the gene 
amplifying of CHOP are listed below. It was confirmed that there was no CHOP gene 
expression in CHOP-/- mice. 
Table 1: Components of Solution A (100mL) 
NaOH 100 mg 
EDTA 7.4 mg 
H2O 100 mL 
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Table 2: Components of Solution B (100mL) 
Tris-HCl (40mM, pH=5.0) 0.48 g 
H2O 100 mL 
 
Table 3: Components of PCR System (25µL) 
10X Buffer 2.5 µL 
2.5 mM dNTP 2 µL 
 Taq DNA polymerase (5U/µL) 0.25 µL 
25uM Primer 0.4 µL 
H2O 17.85 µL 
Template DNA 2 µL 
Table 4: Protocol of PCR for CHOP-/- Mouse 
Step Temperature (ºC) Time 
1 94 2 min 
2 94 20 sec 
3 65（- 0.5 ºC per cycle decrease） 15 sec 
4 68 10 sec 
5 Repeat step 2-4 for 10 cycles 
6 94 15 sec 
7 60 15 sec 
8 72 10 sec 
9 Repeat step 6-8 for 30 cycles 
10 72 2 min 
11 10 ∞ 
 
2.2 Isolation and culture of neonatal mouse cardiomyocytes 
Primary cardiomyocytes were isolated from neonatal mice born within 24 hours. Briefly, 
after sterilizing with 75% alcohol, the neonatal mice were killed by decapitation. The chest 
was opened through a sternal approach and the hearts were harvested and placed into D-
Hank's solution (50 mL tube, Table 5). The hearts were washed in D-Hank's solution 2 
times to remove the blood. Then, each heart was cut into 5–6 pieces by a surgical blade 
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and washed in D-Hank's solution for the third time. The heart pieces were then subjected 
to the following 3 steps of digestion. (1) Heart tissues were incubated with Liberase 
Blendzyme (2.5 mg/mL, Roche Applied Science) which was dissolved in sterile water in a 
water bath at 37°C for 10 min. The supernatant was discarded. (2) The tissues were 
incubated with fresh Liberase Blendzyme solution at 37°C for 15 min. During the 
incubation, the heart pieces were gently shaken every 5 min. After 15 min, the heart pieces 
were triturated to isolate the cardiomyocytes completely. The supernatant containing 
isolated cardiomyocytes was collected and the culture medium DMEM containing 10% 
NBCS (new-born calf serum) (Wisent Inc) was added to stop the digestion. (3) Step 2 
described above was repeated. The supernatants from steps 2 and 3 were pooled and 
centrifuged at 200 g for 5 min. The pellets containing the isolated cardiomyocytes were re-
suspended in 10% NBCS DMEM. Next, the suspended cells were seeded in a culture dish 
which was placed in a CO2 incubator at 37°C for 120 min. This step allowed the fibroblasts 
to adhere to the culture plate. After fibroblast adherence, cardiomyocytes were collected 
and the cell number was counted. The cardiomyocytes were then seeded into a culture plate 
which had been already plated with 1% gelatin (Sigma) at 37°C for 120 min in an incubator. 
Finally, the plate containing cardiomyocytes was placed in a CO2 incubator at 37°C. After 
overnight incubation, the cardiomyocytes were ready for various experiments. The 
neonatal cardiomyocytes were characterized by the staining of tropnin and the purity level 
was more than 95%. 
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Table 5: Components of D-Hanks (1L) 
KCl 0.4 g 
KH2PO4 0.06 g 
NaCl 8 g 
D-Glucose 1 g 
Phenol red 0.012 g 
2.3  Adenoviral infection 
Primary neonatal mouse cardiomyocytes were infected with recombinant adenoviral 
vectors expressing junctophilin-2 (Ad-JPH2), shRNA for junctophilin-2 (Ad-shJPH2), 
green fluorescent protein (Ad-GFP) or human influenza hemagglutinin (aa98-106) peptide 
tag (Ad-HA). The adenoviral vectors were purchased from Vector Biolabs or SignaGen 
Laboratories. The shRNA sequence of junctophilin-2 (Ad-shJPH2, mouse) is 
CCTACATGGGCGAGTGGAA-TTCAAGAGA-TTCCACTCGCCCATGTAGG-
TTTTTT and the Genbank RefSeq is NM_021566. The titer of the recombinant adenovirus 
was calculated based on its cytopathic effect (CPE) and the neonatal cardiomyocytes were 
infected at a multiplicity of infection (MOI) of 100 plaque forming units per cell (100 
PFU/cell). The day before the infection, neonatal cardiomyocytes were seeded in a 24-well 
plate. The adenoviruses were thawed on ice, prepared in 10% NBCS DMEM and added to 
the cardiomyocytes. After incubation for 4 hours at standard cell culture condition, the 
cardiomyocytes were supplied with fresh culture medium. Neonatal cardiomyocytes were 
collected for the following experiments. All the experiments were completed within 72 
hours after adenoviral infection.  
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2.4 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
(SDS-PAGE) and western blot analysis 
Cardiomyocytes were lysed with a cell lysis buffer (Table 6) and collected in microtubes 
(1.5 mL). The cell lysates were disrupted by ultrasonic processor for 3 seconds and 
centrifuged at 10,000 g for 10 min. Then, the protein concentration was detected by the 
Bradford assay (Bio-Rad). In brief, the standards or samples were added to a 96-well plate. 
Then, reagent A and reagent S were added to the well. In this step, proteins and copper 
reacted in an alkaline medium. After that, reagent B was added to the well. In this step, 
Folin reagent was reduced by the copper-treated protein and produced a characteristic blue 
color which was detected at 490 nm. The standard curve was made and the concentration 
of the proteins was calculated according to the color change. After that, the supernatant of 
cell lysates was transferred into a new tube and adjusted to the same concentration by the 
lysis buffer. The 6 X loading buffer (Table 7) was diluted with the supernatant of cell 
lysates and the protein supernatant was incubated in a metal bath at 100 °C for 5 min to 
denature the proteins.   
Table 6: Components of Lysis Buffer (100 mL) 
Tris-HCl (1M, pH=7.5) 5 mL 
SDS 0.5 g 
EDTA (0.5M) 200 µL 
H2O 94.8 mL 
Table 7: Components of 6X Loading Buffer (100 mL) 
Tris-HCl (1M, pH=6.8) 37.5 mL 
SDS 6 g 
Bromophenol blue 30 mg 
Glycerol 48 mL 
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β-Mercaptoethanol 9 mL 
H2O 5.5 mL 
 
After preparation of protein samples, the proteins were separated by SDS-PAGE. The gel 
casting apparatus (Bio-Rad) was assembled and tested for leaking before the SDS-PAGE. 
A resolving gel (Table 8) was then prepared and the concentration of which was dependent 
on the size of the target protein in the samples. The mixture was transferred to the gel 
casting apparatus and a water overlay was filled on the top of the resolving gel to avoid the 
air interference. When the resolving gel had solidified after 30 min, the stacking gel was 
made (Table 9) and filled on the top of the resolving gel. A clean comb was inserted into 
the stacking gel to make space for the protein samples. The gel assembly was taken out of 
the casting and put into the gel tank. Running buffer (Table 10) was poured into the tank 
until above the top of the gel. 30 µg protein sample was loaded in the stacking gel well. 
Then, the electrophoresis assembly was connected to the power supply set at 80V for 30 
min and 100V for about 90 min until the running front reached the end of the gel. 
Table 8: Components of Resolving Gel (10mL) 
Concentration 10% 12% 
H2O 2.7 mL 2.05 mL 
30% Acrylamide 3.35 mL 4 mL 
Tris (1.5M, pH=8.8) 3.75 mL 3.75 mL 
10% SDS 100 µL 100 µL 
10% Ammonium persulfate (APS) 100 µL 100 µL 
TEMED 4 µL 4 µL 
Table 9: Components of Stacking Gel (3mL) 
H2O 2.05 mL 
30% Acrylamide 0.5 mL 
Tris (1.5M, pH=8.8) 0.375 mL 
10% SDS 30 µL 
  
29 
10% Ammonium persulfate (APS) 
 
30 µL 
TEMED 3 µL 
Table 10: Components of Running Buffer (1L) 
Tris base 3.03 g 
Glycine 14.41 g 
SDS 1 g 
H2O 1000 mL 
pH 8.3 
After electrophoresis, the separated proteins were transferred to a polyvinyl difluoride 
(PVDF) membrane (Froggabio). First, the transfer cassette equipment was immersed in 
transfer buffer (Table 11) and the PVDF membrane was immersed in methanol. Next, the 
cassettes were assembled in a sandwich structure: a sponge, a layer of blotting paper, a 
PVDF membrane, electrophoresed gel, a layer of blotting paper and a sponge. Then, the 
cassette was placed in the tank filled with transfer buffer and connected to the power supply 
set at 350 mA for 90 min at 4°C.  
Table 11: Components of Transfer Buffer (1L) 
Tris base 3.03 g 
Glycine 14.41 g 
Methanol 200 mL 
H2O 800 mL 
Upon completion of the run, the PVDF membrane was removed and placed in a blocking 
buffer containing 5% non-fat milk at room temperature for 1 hour. The blocking buffer was 
made by dissolving non-fat milk (Bio Basic) in tris-buffered saline containing Tween 20 
(TBST, Table 12). This step was to block the non-specific binding sites. After that, the 
primary antibodies were diluted with 5% bovine serum albumin (BSA, Sigma) in TBST 
and the PVDF membranes were incubated with the primary antibodies in a tube which was 
set on a rocking table at 4 °C, overnight. After incubation with the primary antibodies, the 
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PVDF membranes were washed 3 times with TBST for 10 min each. The membranes were 
then incubated with the secondary antibodies in a solution containing 5% non-fat milk in 
TBST at room temperature for 1 hour. After incubation with the secondary antibodies, the 
PVDF membranes were washed 3 times with TBST for 10 min each. Finally, the 
membranes were immersed in enhanced chemiluminescence (ECL) reagent (Table 13) for 
signal detection. The signal was visualized by an enhanced chemiluminescence-detection 
system.  
Table 12: Components of TBST (1L) 
Tris base 2.42 g 
NaCl 8 g 
H2O 1000 mL 
pH 7.6 
 
 
Table 13: Components of Enhanced Chemiluminescence (ECL) Reagent (100mL) 
 Reagent A Reagent B 
Tris-HCl (1M, PH=8.5) 100 mL 100 mL 
Cumaric acid (90mM) 440 µL - 
Luminol (250mM) 1 mL - 
H2O2 - 60 µL 
Table 14: Antibody Information for Western Blot 
Antibody (Polyclonal) Company Molecular weight (kDa) Working 
Cconcentration 
JPH2 (Mouse) Abcam 97 1:1000 
CHOP (Rabbit) Cell Signaling 27 1:1000 
GAPDH (Mouse) Santa Cruz 37 1:400 
Actin (Rabbit) Cell Signaling 42 1:1000 
2.5 Caspase-3 activity measurement 
Activated caspase-3 in neonatal mouse cardiomyocytes was determined by a caspase-3 
activity assay kit according to the manufacturer's protocol (BIOMOL Research 
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Laboratories). The cardiomyocytes were lysed with a lysis buffer (Table 15). The cell 
lysates were collected and centrifuged at 10,000 g for 10 min at 4 °C. The supernatant was 
transferred to a clean tube and the protein concentration was measured by the Bradford 
assay as described above. Then, 100 µg of protein supernatant was added to the 96-well 
black plate. The equal volumes of assay buffer (Table 15) containing the substrate Ac- 
DEVD-AMC (Cayman Chemical Company) or Ac-DEVD-AMC inhibitor AC-DEVD-
CHO (Cayman Chemical Company) was also added to the plate. The substrate Ac- DEVD-
AMC was cleaved by caspase-3 and the released chromophore AMC was detected by a 
fluorescence spectrophotometer. After that, the plate was incubated at 37 °C for 2 hours 
and the fluorescence intensity of cleaved AMC was quantified by a fluorescence 
spectrophotometer with excitation of 355 nm and emission of 460 nm. The fluorescence 
signals were read every 30 min. 
Table 15: Components of Lysis/Assay Buffer (100mL) 
 Lysis buffer Assay buffer 
HEPES (1 M, pH=7.4) 5 mL 5 mL 
CHAPS 0.1 g 0.1 g 
NaCl - 585 mg 
DTT (1 M) 500 µL 1 mL 
EDTA (0.5 M) 20 µL 200 µL 
NP-40 100 µL - 
Glycerol - 10 mL 
H2O 94.4 mL 83.8 mL 
2.6 Cellular DNA fragmentation measurement 
DNA fragmentation was detected by a Cellular DNA Fragmentation ELISA kit (Roche 
Applied Science) according the manufacturer’s instructions. The neonatal mouse 
cardiomyocytes were pre-treated with BrdU labeling reagent for about 20 hours. After 
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various treatments, cells were washed with phosphate buffered saline (PBS, Table 16) 
twice and lysed with 1X incubation buffer. After incubation for 30 min at room temperature, 
the cell lysates were collected and centrifuged at 250 g for 10 min at 4 °C. The supernatant 
was collected and its protein concentration was measured by the Bradford assay. A 96-well 
plate was pre-coated with 1X anti-DNA antibody at 4 °C overnight. After that, the pre-
coated 96-well plate was blocked with 1X incubation buffer at room temperature for 30 
min. Then, the 96-well plate was washed 3 times with 1X washing buffer, 2-3 min each 
time. 200 µg of protein supernatant was added into the 96-well plate for 90 min at room 
temperature or at 4 °C overnight. In this step, the BrdU-labeled DNA fragments bound to 
the immobilized anti-DNA antibody. After that, the supernatants were discarded and the 
96-well plate was washed twice, 2-3 min each time. After the third wash, the 96-well plate 
with a washing buffer was placed in a microwave at middle power for 5 min. Then, the 96-
well plate was cooled for 10 min at -20 °C. In this step, BrdU-labeled DNA fragments were 
denatured and fixed on the bottom of the 96-well plate. The washing buffer was discarded 
and the secondary antibody anti-BrdU-peroxidase was added into the 96-well plate and 
incubated at room temperature for 90 min. Similarly, after incubation, the reaction solution 
containing the secondary antibody was discarded and the 96-well plate was washed 3 times, 
2-3 min each time. Then, the TMB substrate was added to each well and incubated for 
about 10 min at room temperature and the reaction was stopped by a stop buffer. Finally, 
the absorbance value in the 96-well plate was measured with excitation of 355 nm and 
emission of 450 nm.  
Table 16: Components of PBS (1L) 
NaCl 8 g 
KCl 0.2 g 
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Na2HPO4 3.58 g 
KH2PO4 0.24 g 
2.7 Oleate/Palmitate (OA/PA) solution preparation 
Stock solutions for 20 mM OA and 20 mM PA were prepared as follows. OA (Sigma) and 
PA (Sigma) were dissolved in 0.1 M NaOH by heating at 70°C. A 20% bovine serum 
albumin (BSA) solution was prepared in H2O. The OA or PA stock solution was mixed 
with a 20% BSA solution followed by incubation for 10 min at 55 °C to prepare a 10 mM 
OA/PA-10% BSA complex solution. The complex solution was cooled to room 
temperature and filtered through a polyethersulfone membrane (pore size 0.1 µm) for 
sterilization. The complex solutions were heated for 15 min at 55 °C, then cooled to room 
temperature before use. 
2.8 Cytoplastic free Ca2+ detection 
Neonatal mouse cardiomyocytes were seeded in the 96-well black plate with a transparent 
bottom. After various treatments, the cardiomyocytes were ready for staining. Fura-2 was 
a Ca2+ imaging dye that binds to free Ca2+. Fura-2 AM was the cell-permeable 
acetoxymethyl (AM) ester form of Fura-2. Fura-2 AM (Invitrogen) was diluted in culture 
medium (10% NBCS DMEM). The final concentration was 4 µM. Then, Fura-2 AM was 
added to the 96-well black plate and incubated at 37 °C for 60 min. The plate was washed 
3 times with HBSS (Hank’s balanced salt solution, Gibco) and the fluorescence intensity 
(R) in the 96-well black plate was measured by a fluorescence spectrophotometer with 
excitation of 340/380 nm and emission of 510 nm. Next, the neonatal cardiomyocytes were 
treated with 0.05% Triton-X 100 (Sigma) which was used to release all of the free Ca2+ in 
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cardiomyocytes to obtain the maximum fluorescence signal (RTriton-X 100). Similarly, the 
fluorescence intensity was detected by a fluorescence spectrophotometer with excitation of 
340/380 nm and emission of 510 nm. Then, the cardiomyocytes were treated with 20 mM 
EGTA (Bio Basic) to block the free Ca2+ which was applied to acquire the minimum 
fluorescence signal （REGTA ） . The fluorescence intensity was also determined as 
described before (157). Finally, the concentration of cytoplastic free Ca2+ was calculated 
according to the formula: [ Ca2+]i = Kd × [ (R - REGTA)/(RTriton-X 100 - R) ] × (F380 EGTA/F380 
Triton-X 100). (Kd = 225 nM, R = F340/F380) 
2.9 Statistical analysis 
All data were presented as mean ± standard deviation (SD). Results were analyzed by one-
way or two-way ANOVA as appropriate, followed by Fisher’s LSD test or  Newman-Keuls 
test for multi-group comparisons. A Student’s t-test was used for comparison between 2 
groups. The value P < 0.05 was considered statistically significant.  
 
Table 17: Reagent Information 
Name Company Cat Number 
Taq DNA polymerase FroggaBio (Toronto, Canada) T-500 
Liberase Blendzyme Roche （Basel, Switzerland） 05401151001 
DMEM Wisent Inc （Quebec,Canada） 319010CL 
NBCS Gibco （California,America） 26010-074 
Gelatin Sigma （Missouri, America） G9382 
Ad-JPH2 Vector biolabs （Malvern, America） ADV-212592 
Ad-shJPH2 Vector biolabs（Malvern, America） Customized 
Ad-GFP SignaGen laboratories （Rockville, America） SL100708 
Ad-HA Vector biolabs （Malvern, America） ADV-294343 
（Malvern, 
America） 
Bradford assay Bio-Rad （California,America） 500-0001 
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PVDF membrane Froggabio (Toronto, Canada) TM300 
Non-fat milk Bio Basic (Toronto, Canada) NB0669 
Tween 20 Sigma（Missouri, America） P9416 
BSA Sigma（Missouri, America） A9647 
Ac-DEVD-AMC Cayman Chemical （Michigan, America） 14986 
Ac-DEVD-CHO Cayman Chemical （Michigan, America） 10017 
DNA fragmentation 
ELISA kit 
Roche （Basel, Switzerland） 11585045001 
Oleate Sigma（Missouri, America） O7501 
Palmitate Sigma（Missouri, America） P9767 
Fura-2 AM eBioscience（California,America） 65085839 
HBSS Gibco（California,America） 14065056 
Triton X-100 Sigma（Missouri, America） T9284 
EGTA Bio Basic (Toronto, Canada) ED0077 
NaOH VWR （Pennsylvania, America） BDH7222-1 
EDTA Sigma（Missouri, America） E5134 
Tris Bio Basic (Toronto, Canada) TB0196 
HCl Sigma（Missouri, America） HX0603-4 
KCl Sigma（Missouri, America） PX1405-1 
KH2PO4 Bio Basic (Toronto, Canada) PB0445 
NaCl Bio Basic (Toronto, Canada) DB0483 
D-Glucose Bio Basic (Toronto, Canada) GB0219 
Phenol red Sigma（Missouri, America） P5530 
SDS Sigma（Missouri, America） L3771 
Bromophenol Blue Sigma（Missouri, America） 20017 
Glycerol Sigma（Missouri, America） G5516 
β-Mercaptoethanol	 Sigma（Missouri, America） 444203 
Acrylamide Bio Basic (Toronto, Canada) AB1032 
APS Bio Basic (Toronto, Canada) AB0072 
TEMED Bio Basic (Toronto, Canada) TB 0508 
Glycine Bio Basic (Toronto, Canada) GB0235 
Methanol VWR（Pennsylvania, America） BDH1135-4LP 
Coumeric acid Sigma（Missouri, America） C9008 
Luminol Sigma（Missouri, America） A8511 
HEPES Bio Basic (Toronto, Canada) HB0264 
CHAPS Bio Basic (Toronto, Canada) CD0110 
  
36 
DTT Bio Basic (Toronto, Canada) DB0058 
NP-40 Sigma（Missouri, America） 13021 
Na2HPO4 Sigma（Missouri, America） S0876 
Ryanodine Abcam （Cambridge, England） ab120083 
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Chapter 3  
3 Results 
3.1 Palmitate incubation increases caspase-3 activity in cultured 
neonatal mouse cardiomyocytes 
It was reported that palmitate was able to cause apoptosis in cardiomyocytes (158-161). To 
confirm this finding in our study, neonatal mouse cardiomyocytes were treated with 
palmitate (PA), a main saturated free fatty acid in western diet, and oleate (OA) served as 
a control. Palmitate has been widely applied in the study of cardiac lipotoxicity. Most of 
the studies show that the concentration of palmitate ranges from 100 µM to 1200 µM (162-
168). We tried 200 µM, 400 µM and 800 µM palmitate to treat neonatal cardiomyocytes 
and found the concentration of 800 µM showed the best induction of apoptosis in 
cardiomyocytes compared to oleate. Since then, we used this concentration of palmitate for 
the following studies. Neonatal mouse cardiomyocytes were treated with PA (800 µM) or 
OA (800 µM) for 48 hours. Then, caspase-3 activity was measured to indicate the apoptosis 
in cardiomyocytes. Palmitate incubation increased caspase-3 activity by 60% in neonatal 
cardiomyocytes compared to OA group (Figure 3). 
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Figure 3: Palmitate incubation increases caspase-3 activity in neonatal mouse 
cardiomyocytes.  
            Neonatal mouse cardiomyocytes were isolated and cultured for 24 hours. After 
incubation with oleate (OA) or palmitate (PA) for 48 hours, the apoptosis in 
neonatal mouse cardiomyocytes was analyzed by the measurement of caspase-3 
activity. Data was mean ± SD from 4 independent experiments and analyzed by 
unpaired Student’s t-test.  * P < 0.05 versus OA. 
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3.2 Palmitate incubation increases DNA fragmentation in cultured 
neonatal mouse cardiomyocytes 
Neonatal mouse cardiomyocytes were treated with PA (800 µM) or OA (800 µM) for 48 
hours. Then, DNA fragmentation was measured to indicate the apoptosis in 
cardiomyocytes. PA incubation increased DNA fragmentation by 50% in neonatal 
cardiomyocytes relative to OA group (Figure 4). These results (Figure 3 and 4) confirmed 
that palmitate incubation induces apoptosis in cultured neonatal mouse cardiomyocytes 
when compared to oleate. 
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Figure 4: Palmitate incubation increases DNA fragmentation in neonatal mouse 
cardiomyocytes. 
            Neonatal mouse cardiomyocytes were isolated and cultured for 24 hours. After 
incubation with oleate (OA) or palmitate (PA) for 48 hours, the apoptosis in 
neonatal mouse cardiomyocytes was analyzed by the measurement of DNA 
fragmentation. Data was mean ± SD from 3 independent experiments and analyzed 
by unpaired Student’s t-test. * P < 0.05 versus OA. 
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3.3 Palmitate incubation reduces JPH2 expression in cultured 
neonatal mouse cardiomyocytes 
The expression of JPH2 was down-regulated in many cardiac diseases (35, 36). Prior study 
from our lab showed that the protein levels of JPH2 were reduced in the hearts of mice fed 
with high fat diet for 4 months (2). To confirm this, neonatal mouse cardiomyocytes were 
treated with 800 uM PA or OA for 48 hours. The protein levels of JPH2 were determined 
by western blot analysis. PA incubation decreased JPH2 expression by 30% in neonatal 
mouse cardiomyocytes compared to OA group (Figure 5). This result indicated that 
palmitate incubation reduces JPH2 expression in neonatal mouse cardiomyocytes when 
compared to oleate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
42 
 
 
 
Figure 5: Palmitate incubation reduces JPH2 protein expression in neonatal mouse 
cardiomyocytes.  
            Neonatal mouse cardiomyocytes were isolated and cultured for 24 hours. After 
incubation with oleate (OA) or palmitate (PA) for 48 hours, the protein levels of 
JPH2 were analyzed by western blot analysis. GAPDH was used as a loading 
control. Upper panel: a representative western blot for JPH2 and GAPDH from 4 
different cultures with each in duplicate; lower panel: quantitation of the protein 
levels of JPH2 relative to GAPDH. Data was mean ± SD from 4 independent 
experiments and analyzed by unpaired Student’s t-test. * P < 0.05 versus OA. 
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3.4 Knockdown of JPH2 in cultured neonatal mouse 
cardiomyocytes 
To study the influence of JPH2 down-regulation in neonatal mouse cardiomyocytes, we 
used an adenoviral vector containing shJPH2 (Ad-shJPH2) to knock down JPH2. An 
adenoviral vector containing GFP (Ad-GFP) served as a control. Neonatal mouse 
cardiomyocytes were infected with Ad-shJPH2 (30, 60 or 100 PFU/cell) or Ad-GFP (100 
PFU/cell). 48 hours later, the protein levels of JPH2 were determined by western blot 
analysis. The protein levels of JPH2 were reduced in cardiomyocytes infected with Ad-
shJPH2 compared to Ad-GFP group by 30%, 60% and 80% (Figure 6). This result 
indicated a successful knowdown of JPH2 by Ad-shJPH2 in cardiomyocytes. Since the 
dose of 100 PFU/cell showed the best knowdown of JPH2, we used this dose of Ad-shJPH2 
for the following studies. 
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Figure 6: Knockdown of JPH2 with Ad-shJPH2 in neonatal mouse cardiomyocytes.  
            Neonatal mouse cardiomyocytes were isolated and cultured for 24 hours. The cells 
were infected with Ad-shJPH2 or Ad-GFP. 48 hours later, the protein levels of 
JPH2 in neonatal cardiomyocytes were analyzed by western blot. Actin was used 
as a loading control. Upper panel: a representative western blot for JPH2 and Actin 
from 3 different cultures with each in duplicate. Lower panel: quantitation of the 
protein levels of JPH2 relative to Actin. Data was mean ± SD from 3 independent 
experiments, and analyzed by one-way ANOVA followed by Fisher’s LSD test. 
            * P < 0.05 versus Ad-GFP. 
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3.5 JPH2 knockdown enhances palmitate-induced caspase-3 
activity in cultured neonatal mouse cardiomyocytes 
To investigate whether JPH2 knockdown enhanced palmitate-induced cardiomyocyte 
injury, we knocked down JPH2 in cardiomyocytes and treated the cardiomyocytes with PA. 
Neonatal mouse cardiomyocytes were infected with Ad-shJPH2 (100 PFU/cell) or Ad-GFP 
(100 PFU/cell) for 24 hours and then treated with 800 µM PA or OA for another 24 hours. 
The caspase-3 activity was measured to indicate apoptosis. Knockdown of JPH2 solely 
induced higher caspase-3 activity by 330% compared to the Ad-GFP group, indicating 
apoptotic cell death. Similarly, treatment with PA solely also resulted in higher caspase-3 
activity by 100% compared with OA group. Furthermore, palmitate-induced apoptosis was 
enhanced by knockdown of JPH2 by 160% as determined by caspase-3 activity (Figure 7).  
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Figure 7: JPH2 knockdown enhances palmitate-induced caspase-3 activity in 
neonatal mouse cardiomyocytes. 
            Neonatal mouse cardiomyocytes were isolated and cultured for 24 hours. After 
infection with Ad-shJPH2 or Ad-GFP, together with incubation with oleate (OA) 
or palmitate (PA) for 48 hours, apoptosis in neonatal mouse cardiomyocytes was 
analyzed by the measurement of caspase-3 activity. Data was mean ± SD from 5 
independent experiments and analyzed by two-way ANOVA followed by 
Newman-Keuls test. * P < 0.05 versus OA-Ad-GFP, # P < 0.05 versus PA-Ad-GFP. 
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3.6 JPH2 knockdown enhances palmitate-induced DNA 
fragmentation in cultured neonatal mouse cardiomyocytes 
Neonatal mouse cardiomyocytes were infected with Ad-shJPH2 (100 PFU/cell) or Ad-GFP 
(100 PFU/cell) for 24 hours and then treated with 800 µM PA or OA for another 24 hours. 
DNA fragmentation was measured to indicate the apoptosis. Knockdown of JPH2 solely 
induced greater DNA fragmentation by 100% compared to Ad-GFP group, indicating 
apoptotic cell death. Similarly, treatment of PA solely also induced greater DNA 
fragmentation by 40% compared to OA group. Furthermore, palmitate-induced apoptosis 
was exacerbated by JPH2 knockdown by 65%  as measured by DNA fragmentation (Figure 
8). These results (Figure 7 and 8) demonstrated that JPH2 knockdown enhances palmitate-
induced apoptosis in neonatal cardiomyocytes. 
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Figure 8: JPH2 knockdown enhances palmitate-induced DNA fragmentation in 
neonatal mouse cardiomyocytes. 
            Neonatal mouse cardiomyocytes were isolated and cultured for 24 hours. After 
infection with Ad-shJPH2 or Ad-GFP, together with incubation with oleate (OA) 
or palmitate (PA) for 48 hours, apoptosis in neonatal mouse cardiomyocytes was 
analyzed by the measurement of DNA fragmentation. Data was mean ± SD from 
3 independent experiments and analyzed by two-way ANOVA followed by 
Newman Keuls test. * P < 0.05 versus OA-Ad-GFP, # P < 0.05 versus PA-Ad-GFP. 
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3.7 Over-expression of JPH2 in cultured neonatal mouse 
cardiomyocytes  
To up-regulate JPH2 expression, we used an adenoviral vector containing JPH2 (Ad-JPH2). 
An adenoviral vector containing human influenza hemagglutinin (aa 98-106) peptide tag 
(Ad-HA) served as a control. Neonatal mouse cardiomyocytes were infected with Ad-JPH2 
(10, 20 and 40 PFU/cell) or Ad-HA (40 PFU/cell). 48 hours later, the protein levels of 
JPH2 were determined by western blot analysis. The protein levels of JPH2 were higher 
by 40%, 200% and 300% in cardiomyocytes infected with Ad-JPH2 compared to Ad-HA 
group (Figure 9). This result indicated a successful over-expression of JPH2 by Ad-JPH2 
in cardiomyocytes. Since the dose of 40 PFU/cell showed the best over-expression of JPH2, 
we used this dose of Ad-JPH2 for the following studies. 
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Figure 9: Over-expression of JPH2 with Ad-JPH2 in neonatal mouse cardiomyocytes.  
            Neonatal mouse cardiomyocytes were isolated and cultured for 24 hours. After 
infection with Ad-JPH2 or Ad-HA for 48 hours, the protein levels of JPH2 in 
neonatal cardiomyocytes were analyzed by western blot. Actin was used as a 
loading control. Upper panel: a representative western blot for JPH2 and Actin from 
3 different cultures, each in duplicate. Lower panel: quantitation of the protein 
levels of JPH2 relative to Actin. Data was mean ± SD from 3 independent 
experiments and analyzed by one-way ANOVA followed by Fisher’s LSD test.  
            * P < 0.05 versus Ad-HA. 
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3.8 JPH2 over-expression attenuates palmitate-induced caspase-3 
activity in cultured neonatal mouse cardiomyocytes 
To determine whether JPH2 over-expression had a protective role in palmitate-induced cell 
injury, we over-expressed JPH2 in cardiomyocytes and treated the cardiomyocytes with 
PA. Neonatal mouse cardiomyocytes were infected with Ad-JPH2 (40 PFU/cell) or Ad-
HA (40 PFU/cell) for 24 hours and then treated with 800 µM PA or OA for another 24 
hours. Caspase-3 activity was measured to indicate the apoptosis. JPH2 over-expression 
solely reduced caspase-3 activity by 60% compared to Ad-HA group. PA treatment 
resulted in greater caspase-3 activity by 50% in neonatal cardiomyocytes compared to OA 
group, indicative of apoptotic cell death. However, PA-induced caspase-3 activity was 
attenuated by the over-expression of JPH2 by 60% in neonatal cardiomyocytes (Figure 10).  
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Figure 10: JPH2 over-expression attenuates palmitate-induced caspase-3 activity in 
neonatal mouse cardiomyocytes. 
            Neonatal mouse cardiomyocytes were isolated and cultured for 24 hours. After 
infection with Ad-JPH2 or Ad-HA, together with incubation with oleate (OA) or 
palmitate (PA) for 48 hours, apoptosis in neonatal mouse cardiomyocytes was 
analyzed by the measurement of caspase-3 activity. Data was mean ± SD from 4 
independent experiments and analyzed by two-way ANOVA followed by 
Newman-Keuls test. * P < 0.05 versus OA-Ad-HA, # P < 0.05 versus PA-Ad-HA. 
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3.9 JPH2 over-expression attenuates palmitate-induced DNA 
fragmentation in cultured neonatal mouse cardiomyocytes 
Neonatal mouse cardiomyocytes were infected with Ad-JPH2 (40 PFU/cell) or Ad-HA (40 
PFU/cell) for 24 hours and then treated with 800 µM PA or OA for another 24 hours. DNA 
fragmentation was further measured to indicate the apoptosis. JPH2 over-expression solely 
reduced DNA fragmentation by 50% compared to Ad-HA group.PA treatment resulted in 
greater DNA fragmentation by 50% in neonatal cardiomyocytes relative to OA group, 
indicating of apoptotic cell death. In contrast, PA-induced DNA fragmentation was 
attenuated by the over-expression of JPH2 by 50% in neonatal cardiomyocytes (Figure 11). 
These results (Figure 10 and 11) indicated that JPH2 over-expression attenuates palmitate-
induced apoptosis in neonatal cardiomyocytes.  
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Figure 11: JPH2 over-expression attenuates palmitate-induced DNA fragmentation 
in neonatal mouse cardiomyocytes. 
            Neonatal mouse cardiomyocytes were isolated and cultured for 24 hours. After 
infection with Ad-JPH2 or Ad-HA, together with incubation with oleate (OA) or 
palmitate (PA) for 48 hours, apoptosis in neonatal mouse cardiomyocytes was 
analyzed by the measurement of DNA fragmentation. Data was mean ± SD from 3 
independent experiments and analyzed by two-way ANOVA followed by Newman 
Keuls test. * P < 0.05 versus OA-Ad-HA, # P < 0.05 versus PA-Ad-HA. 
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3.10 Knockdown of JPH2 induces caspase-3 activity in cultured 
neonatal mouse cardiomyocytes 
We had successfully knocked down JPH2 by Ad-shJPH2 in neonatal mouse 
cardiomyocytes. Next, we wanted to determine whether JPH2 knockdown sufficiently 
induced apoptosis in cardiomyocytes. Similarly, we used Ad-shJPH2 to knockdown JPH2 
and Ad-GFP served as a control. Neonatal cardiomyocytes were infected with Ad-shJPH2 
(100 PFU/cell) or Ad-GFP (100 PFU/cell) for 48 hours. Apoptosis was assessed by 
measuring caspase-3 activity which was the most frequently activated death protease in the 
execution phase of apoptosis. JPH2 knockdown resulted in greater caspase-3 activity by 
210%  in neonatal cardiomyocytes infected with Ad-shJPH2 compared to Ad-GFP group 
(Figure 12). 
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Figure 12: JPH2 knockdown induces caspase-3 activity in neonatal mouse 
cardiomyocytes. 
            Neonatal mouse cardiomyocytes were isolated and cultured for 24 hours. After 
infection with Ad-shJPH2 or Ad-GFP for 48 hours, apoptosis in neonatal mouse 
cardiomyocytes was determined by the detection of caspase-3 activity. Data was 
mean ± SD from 4 independent experiments and analyzed by unpaired Student’s t-
test. * P < 0.05 versus Ad-GFP. 
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3.11 Knockdown of JPH2 increases DNA fragmentation in cultured 
neonatal mouse cardiomyocytes 
Neonatal cardiomyocytes were infected with Ad-shJPH2 (100 PFU/cell) or Ad-GFP (100 
PFU/cell) for 48 hours. Apoptosis was further analyzed by measuring DNA fragmentation, 
which was also a biological hallmark of apoptosis. JPH2 knockdown resulted in greater 
DNA fragmentation by 90% in neonatal cardiomyocytes infected with Ad-shJPH2 
compared to Ad-GFP group (Figure 13). These results (Figure 12 and 13) demonstrated 
that knockdown of JPH2 sufficiently induces apoptosis in cultured neonatal mouse 
cardiomyocytes relative to Ad-GFP group. 
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Figure 13: JPH2 knockdown induces DNA fragmentation in neonatal mouse 
cardiomyocytes.            
           Neonatal mouse cardiomyocytes were isolated and cultured for 24 hours. After 
infection with Ad-shJPH2 or Ad-GFP for 48 hours, apoptosis in neonatal mouse 
cardiomyocytes was determined by the detection of DNA fragmentation. Data was 
mean ± SD from 3 independent experiments and analyzed by unpaired Student’s t-
test. * P < 0.05 versus Ad-GFP. 
 
 
 
 
 
 
 
 
 
  
59 
3.12 Palmitate incubation increases CHOP expression in cultured 
neonatal mouse cardiomyocytes 
To investigate whether palmitate incubation induced ER stress in cardiomyocytes, neonatal 
mouse cardiomyocytes were subjected to palmitate incubation. Neonatal mouse 
cardiomyocytes were treated with 800 µM PA or OA for 24 hours. The protein levels of 
CHOP were determined by western blot as an indicator of ER stress. Similarly, PA 
treatment also induced higher CHOP expression by 120% in neonatal cardiomyocytes 
compared to OA group (Figure 14). This result demonstrated that palmitate incubation 
results in higher CHOP expression, indicating palmitate incubation induces ER stress in 
neonatal cardiomyocytes compared to oleate. 
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Figure 14: Palmitate incubation increases CHOP protein expression in neonatal 
mouse cardiomyocytes. 
            Neonatal mouse cardiomyocytes were isolated and cultured for 24 hours. After 
incubation with oleate (OA) or palmitate (PA) for 24 hours, the protein levels of 
CHOP were analyzed by western blot. Actin was used as a loading control. Upper 
panel: a representative western blot for CHOP and actin from 4 different cultures 
in duplicate. Lower panel: quantitation of the protein levels of CHOP relative to 
actin. Data was mean ± SD from 4 independent experiments and analyzed by 
unpaired Student’s t-test. * P < 0.05 versus OA. 
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3.13 JPH2 knockdown increases CHOP expression in cultured 
neonatal mouse cardiomyocytes 
To determine whether JPH2 knockdown induced ER stress in cardiomyocytes, neonatal 
mouse cardiomyocytes were subjected to Ad-shJPH2 infection. Neonatal mouse 
cardiomyocytes were infected with Ad-shJPH2 (100 PFU/cell) or Ad-GFP (100 PFU/cell) 
for 24 hours. CHOP was detected to indicate the ER stress in neonatal cardiomyocytes. 
The protein levels of CHOP were determined by western blot. JPH2 knockdown resulted 
in higher CHOP expression by 60% in neonatal cardiomyocytes compared to Ad-GFP 
group (Figure 15).  
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Figure 15: JPH2 knockdown increases CHOP protein expression in neonatal mouse 
cardiomyocytes.  
            Neonatal mouse cardiomyocytes were isolated and cultured for 24 hours. After 
infection with Ad-GFP/Ad-shJPH2 for 24 hours, the protein levels of CHOP were 
analyzed by western blot. Actin was used as a loading control. Upper panel: a 
representative western blot for CHOP and actin from 4 different cultures with each 
in duplicate. Lower panel: quantitation of the protein levels of CHOP relative to 
actin. Data was mean ± SD from 4 independent experiments and analyzed by 
unpaired Student’s t-test. * P < 0.05 versus Ad-GFP. 
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3.14 Over-expression of JPH2 attenuates palmitate-induced CHOP 
expression in cultured neonatal mouse cardiomyocytes 
We had shown that both JPH2 knockdown and palmitate incubation induced ER stress and 
apoptosis in cardiomyocytes, and over-expression of JPH2 protected cardiomyocytes 
against palmitate-induced apoptosis. Therefore, we were curious whether this protective 
role of JPH2 was dependent on preventing ER stress. To investigate if JPH2 over-
expression attenuated palmitate-induced ER stress in cardiomyocytes, we over-expressed 
JPH2 in neonatal cardiomyocytes first and then treated the cardiomyocytes with palmitate. 
Neonatal mouse cardiomyocytes were infected with Ad-JPH2 (40 PFU/cell) or Ad-HA (40 
PFU/cell) for 24 hours. Then, the cardiomyocytes were treated with 800 µM PA or OA for 
24 hours. CHOP expression was detected to indicate the ER stress in neonatal 
cardiomyocytes. The protein levels of CHOP were determined by western blot. PA 
treatment resulted in greater CHOP expression by 260% in cardiomyocytes compared to 
OA group, indicating of ER stress. JPH2 over-expression prevented palmitate-induced 
CHOP expression by 40% in neonatal cardiomyocytes (Figure 16). This result indicated 
that JPH2 over-expression attenuates palmitate-induced ER stress in neonatal 
cardiomyocytes. 
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Figure 16: JPH2 over-expression attenuates palmitate-induced CHOP protein 
expression in neonatal mouse cardiomyocytes. 
            Neonatal mouse cardiomyocytes were isolated and cultured for 24 hours. After 
infection with Ad-JPH2 or Ad-HA and incubation with oleate (OA) or palmitate 
(PA), the protein levels of CHOP were analyzed by western blot. GAPDH was used 
as a loading control. Upper panel: a representative western blot for CHOP and 
GAPDH from 3 different cultures in duplicate. Lower panel: quantitation of the 
protein levels of CHOP relative to GAPDH. Data was mean ± SD from 3 
independent experiments and analyzed by two-way ANOVA followed by 
Newman-Keuls test. * P < 0.05 versus OA-Ad-HA, # P < 0.05 versus PA-Ad-HA. 
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3.15 CHOP knockout reduces JPH2 knockdown-induced caspase-3 
activity in cultured neonatal mouse cardiomyocytes 
To determine if JPH2 knockdown induced apoptosis by CHOP up-regulation in 
cardiomyocytes, we isolated neonatal cardiomyocytes from wild type (WT) or CHOP 
knockout (CHOP-/-) mice. Neonatal mouse cardiomyocytes from WT/CHOP-/- mice were 
infected with Ad-shJPH2 (100 PFU/cell) or Ad-GFP (100 PFU/cell) for 48 hours. Then, 
caspase-3 activity was measured to indicate apoptosis in cardiomyocytes. As observed 
earlier, JPH2 knockdown resulted in greater caspase-3 activity by 210% in WT 
cardiomyocytes (Figure 17). CHOP knockout resulted in lower JPH2 knockdown-induced 
caspase-3 activity by 15% in neonatal cardiomyocytes (Figure 17).  
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Figure 17: CHOP knockout reduces JPH2 knockdown-induced caspase-3 activity in 
neonatal mouse cardiomyocytes.  
        Neonatal mouse cardiomyocytes were isolated and cultured for 24 hours. After 
infection with Ad-shJPH2 or Ad-GFP for 48 hours, caspase-3 activity was analyzed 
in neonatal mouse cardiomyocytes from WT/CHOP-/- mice. Data was mean ± SD from 
8 independent experiments and analyzed by two-way ANOVA followed by Newman 
Keuls test. * P < 0.05 versus Ad-GFP-WT, # P < 0.05 versus Ad-shJPH2-WT. 
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3.16 CHOP knockout reduces palmitate-induced caspase-3 activity 
in cultured neonatal mouse cardiomyocytes 
To determine if palmitate induced apoptosis through CHOP up-regulation in 
cardiomyocytes, we isolated neonatal cardiomyocytes from wild type (WT) or CHOP 
knockout (CHOP-/-) mice. Neonatal cardiomyocytes from WT/CHOP-/- mice were treated 
with 800 µM PA or OA for 48 hours. Then, caspase-3 activity was measured to indicate 
apoptosis in cardiomyocytes. CHOP knockout solely reduced caspase-3 activity by 40% 
compared to WT cardiomyocytes. PA incubation resulted in greater caspase-3 activity by 
70% in WT cardiomyocytes when compared to oleate (Figure 18). CHOP knockout 
attenuated palmitate-induced caspase-3 activity by 40% in neonatal cardiomyocytes 
(Figure 18). These results (Figure 17 and 18) indicated that CHOP knockout reduces JPH2 
knockdown or palmitate-induced caspase-3 activity, indicating CHOP induction is an 
important factor contributing to apoptosis caused by JPH2 knockdown or palmitate 
incubation.  
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Figure 18: CHOP knockout reduces palmitate-induced caspase-3 activity in neonatal 
mouse cardiomyocytes.  
            Neonatal mouse cardiomyocytes were isolated and cultured for 24 hours. After 
incubation with oleate (OA) or palmitate (PA) for 48 hours, caspase-3 activity was 
determined in neonatal cardiomyocytes from WT/CHOP-/- mice. Data was mean ± 
SD from 8 independent experiments and analyzed by two-way ANOVA followed 
by Newman Keuls test. * P < 0.05 versus OA-WT, # P < 0.05 versus PA-WT. 
 
 
 
 
 
 
 
 
 
 
 
 
  
69 
3.17 Inhibition of Ca2+ release from RyR2 reduces palmitate-
induced CHOP expression in cultured neonatal mouse 
cardiomyocytes 
To determine whether palmitate induced CHOP expression through Ca2+ release from 
RyR2, we used ryanodine to block Ca2+ release from RyR2 in cardiomyocytes. To do this, 
neonatal cardiomyocytes were treated with 800 µM PA or OA for 24 hours together with 
incubation with ryanodine (0, 10 and 50 µM). The protein levels of CHOP were determined 
by western blot to indicate ER stress. Palmitate incubation resulted in greater expression 
of CHOP by 100% in cardiomyocytes when compared to oleate (Figure 19). Ryanodine 
resulted in lower palmitate-induced CHOP expression by 30% and 50% in neonatal 
cardiomyocytes (Figure 19). These results demonstrated that inhibition of Ca2+ release 
from RyR2 prevents palmitate incubation-induced CHOP expression, indicating disruption 
of Ca2+ homeostasis participates in palmitate incubation-induced ER stress in 
cardiomyocytes. 
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Figure 19: Inhibition of Ca2+ release from RyR2 reduces palmitate-induced CHOP 
protein expression in neonatal mouse cardiomyocytes. 
            Neonatal mouse cardiomyocytes were isolated and cultured for 24 hours. After 
incubation with oleate (OA) or palmitate (PA) with or without ryanodine treatment 
for 24 hours, the protein levels of CHOP were analyzed by western blot analysis. 
GAPDH was used as a loading control. Upper panel: a representative western blot 
for CHOP and GAPDH from 4 different cultures in duplicate. Lower panel: 
quantitation of the protein levels of CHOP relative to GAPDH. Data was mean ± 
SD from 4 independent experiments and analyzed by two-way ANOVA followed 
by Newman-Keuls test. * P < 0.05 versus OA-0 µM ryanodine, # P < 0.05 versus 
PA-0 µM ryanodine. 
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3.18 Inhibition of Ca2+ release from RyR2 reduces JPH2 
knockdown-induced CHOP expression in cultured neonatal 
mouse cardiomyocytes 
To determine if JPH2 knockdown induced CHOP expression through  Ca2+ release from 
RyR2 in cardiomyocytes, neonatal mouse cardiomyocytes were infected with Ad-shJPH2 
(100 PFU/cell) or Ad-GFP (100 PFU/cell) for 24 hours. At the same time, neonatal 
cardiomyocytes were treated with ryanodine (0, 10 and 50 µM). The protein levels of 
CHOP were determined by western blot to indicate ER stress. JPH2 knockdown resulted 
in greater expression of CHOP by 40% in cardiomyocytes (Figure 20). Ryanodine resulted 
in lower JPH2 knockdown-induced CHOP expression by 25% and 70% in neonatal 
cardiomyocytes (Figure 20).  
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Figure 20: Inhibition of Ca2+ release from RyR2 reduces JPH2 knockdown-induced 
CHOP protein expression in neonatal mouse cardiomyocytes. 
            Neonatal mouse cardiomyocytes were isolated and cultured for 24 hours. After 
infection with Ad-shJPH2 or Ad-GFP with or without ryanodine incubation for 24 
hours, the protein levels of CHOP were analyzed by western blot. GAPDH was 
used as a loading control. Upper panel: a representative western blot for CHOP and 
GAPDH from 4 different cultures in duplicate. Lower panel: quantitation of the 
protein levels of CHOP relative to GAPDH. Data was mean ± SD from 4 
independent experiments and analyzed by two-way ANOVA followed by 
Newman-Keuls test. * P < 0.05 versus Ad-GFP-0 µM ryanodine, # P < 0.05 versus 
Ad-shJPH2-0 µM ryanodine. 
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3.19 Inhibition of Ca2+ release from RyR2 reduces palmitate-
induced apoptosis in cultured neonatal mouse cardiomyocytes 
Since inhibition of Ca2+ release from RyR2 by ryanodine reduced palmitate-induced ER 
stress in cardiomyocytes, we next investigated if ryanodine decreased palmitate-induced 
apoptosis. Neonatal mouse cardiomyocytes were incubated with 800 µM OA or PA for 48 
hours. At the same time, the cardiomyocytes were treated with or without 50 µM ryanodine. 
Caspase-3 activity was detected to indicate apoptosis in neonatal cardiomyocytes. PA 
incubation resulted in greater caspase-3 activity by 80% in cardiomyocytes compared to 
OA group. Ryanodine resulted in lower palmitate-induced caspase-3 activity by 30% in 
neonatal cardiomyocytes (Figure 21). This result demonstrated that inhibition of Ca2+ 
release from RyR2 reduces palmitate-induced apoptosis in cardiomyocytes. 
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Figure 21: Inhibition of Ca2+ release from RyR2 reduces palmitate-induced caspase-
3 activity in neonatal mouse cardiomyocytes. 
            Neonatal mouse cardiomyocytes were isolated and cultured for 24 hours. After 
incubation with oleate (OA) or palmitate (PA) with or without ryanodine treatment 
for 48 hours, caspase-3 activity was analyzed in neonatal mouse cardiomyocytes. 
Data was mean ± SD from 8 independent experiments and analyzed by two-way 
ANOVA followed by Newman-Keuls test. * P < 0.05 versus OA-Vehicle, # P < 
0.05 versus PA-Vehicle. 
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3.20 Ryanodine reduces palmitate-induced Ca2+ release in cultured 
neonatal mouse cardiomyocytes 
Since disruption of Ca2+ homeostasis contributed to ER stress and apoptosis in 
cardiomyocytes (76), we next determined the cytoplasmic free Ca2+ level to further 
investigate if Ca2+ imbalance participated in palmitate-induced cardiomyocyte injury. 
Neonatal mouse cardiomyocytes were incubated with 800 µM OA or PA for 48 hours. At 
the same time, the cardiomyocytes were treated with or without 50 µM ryanodine. Fura-2 
AM was used to stain cytoplasmic free Ca2+ in cardiomyocytes. Ryanodine was 
administrated to inhibit Ca2+ release from RyR2 in cardiomyocytes. PA incubation resulted 
in greater cytoplasmic free Ca2+ by 160% in cardiomyocytes compared to OA group. 
Ryanodine resulted in lower palmitate-induced cytoplasmic free Ca2+ by 50% in neonatal 
cardiomyocytes (Figure 22). This result demonstrated that palmitate incubation induces 
excessive Ca2+ release and ryanodine reduces palmitate-induced Ca2+ release in 
cardiomyocytes. 
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Figure 22 Ryanodine reduces palmitate-induced Ca2+ release in neonatal mouse 
cardiomyocytes.  
            Neonatal mouse cardiomyocytes were isolated and cultured for 24 hours. After 
incubation with oleate (OA) or palmitate (PA) with or without ryanodine treatment 
for 48 hours, cytoplasmic free Ca2+ was analyzed in neonatal mouse 
cardiomyocytes. Data was mean ± SD from 4 independent experiments and 
analyzed by two-way ANOVA followed by Newman-Keuls test. * P < 0.05 versus 
OA-Vehicle, # P < 0.05 versus PA-Vehicle. 
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3.21 JPH2 over-expression attenuates palmitate-induced Ca2+ 
release in cultured neonatal mouse cardiomyocytes 
As mentioned before, JPH2 protected cardiomyocytes against palmitate-induced injury by 
preventing ER stress and subsequent apoptosis. Palmitate incubation increased cytoplasmic 
free Ca2+ relative to oleate, contributing to ER stress and apoptosis in cardiomyocytes. We 
hypothesized that JPH2 protected cardiomyocytes against palmitate-induced ER stress and 
apoptosis through preventing excessive Ca2+ release in cardiomyocytes. To demonstrate 
this, neonatal mouse cardiomyocytes were infected with Ad-JPH2 (40 PFU/cell) or Ad-
HA (40 PFU/cell) for 24 hours and then treated with 800 µM PA or OA for another 24 
hours. Fura-2 AM was used to stain cytoplasmic free Ca2+ in cardiomyocytes. PA 
incubation resulted in greater cytoplasmic free Ca2+ by 100% in cardiomyocytes compared 
to OA group. JPH2 over-expression resulted in lower palmitate-induced cytoplasmic free 
Ca2+ by 45% in neonatal cardiomyocytes (Figure 23). This result demonstrated that JPH2 
over-expression attenuates palmitate-induced Ca2+ release in cardiomyocytes. 
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Figure 23 JPH2 over-expression attenuates palmitate-induced Ca2+ release in 
neonatal mouse cardiomyocytes.   
            Neonatal mouse cardiomyocytes were isolated and cultured for 24 hours. After 
infection with Ad-JPH2 or Ad-HA, together with incubation with oleate (OA) or 
palmitate (PA) for 48 hours, cytoplasmic free Ca2+ was analyzed in neonatal mouse 
cardiomyocytes. Data was mean ± SD from 4 independent experiments and 
analyzed by two-way ANOVA followed by Newman-Keuls test. * P < 0.05 versus 
OA-Ad-HA, # P < 0.05 versus PA-Ad-HA. 
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Chapter 4  
4 Discussion, Limitations and Future Directions 
4.1 Discussion 
The major findings of this study are that silencing of JPH2 enhances, whereas over-
expression of JPH2 reduces palmitate-induced apoptosis in cardiomyocytes. Also, over-
expression of JPH2 attenuates palmitate-induced CHOP expression and apoptosis while 
deletion of CHOP pevents apoptosis in palmitate-stimulated cardiomyocytes. Furthermore, 
over-expression of JPH2 lowers the levels of cytosolic free Ca2+ and blockage of Ca2+ 
release from RyR2 with ryanodine reduces the levels of CHOP protein and inhibits 
apoptosis in palmitate-stimulated cardiomyocytes. Additionally, silencing of JPH2 
sufficiently induces CHOP expression, increases cytosolic free Ca2+ and elicits apoptosis 
in cardiomyocytes. These effects of JPH2 knockdown are prevented by CHOP deletion and 
blockage of Ca2+ release from RyR2. Thus, our study reveals a novel protection of JPH2 
against palmitate-induced apoptosis in cardiomoycytes.  
4.1.1 Palmitate-mediated down-regulation of JPH2 in cardiomyocytes 
A reduction of JPH2 protein has been reported in human diseased hearts including dilated 
cardiomyopathy, hypotrophy and heart failure (36, 43, 169, 170). JPH2 down-regulation 
has also been found in mouse models of heart diseases (53, 58, 171). Studies from our lab 
showed that the protein levels of JPH2 were decreased in high fat diet-fed mouse hearts 
and that in cultured neonatal cardiomoycytes and incubation with palmitate led to a 
reduction of JPH2 protein levels when compared to oleate (2). Consistent with this prior 
report, the present study also shows that palmitate incubation reduces the protein levels of 
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JPH2 in cultured neonatal cardiomyocytes when compared to oleate. These studies suggest 
that JPH2 expression may be altered in cardiomyocytes with metabolic disorders. Although 
palmitate represents an important saturated free fatty acid in western diets, which 
contributes to cardiac lipotoxic injury in metabolic disorders (28), there are other important 
dietary saturated free fatty acids such as myristic acid and stearic acid. It remains to be 
determined if these other saturated free fatty acids also induce down-regulation of JPH2 in 
cardiomyocytes. In addition, it is unknown whether high glucose plays a role in the 
regulation of JPH2 in cardiomyocytes. Currently, we do not know how palmitate causes 
down-regulation of JPH2 protein in cardiomyocytes. A prior study showed that inhibition 
of calpain increased the protein levels of JPH2 in palmitate-stimulated cardiomyocytes and 
high fat diet-fed mouse hearts (2), underscoring an important role of calpain activation in 
down-regulation of JPH2. Indeed, it has been reported that calpain directly cleaves JPH2 
protein at the site of R565T in the C-terminal of JPH2 (172), leading to down-regulation 
of JPH2 during myocardial ischemia/reperfusion injury. In addition to calpain activation, 
alternative mechanisms have also been reported to be contributed to dysregulation of JPH2 
in the heart under stress. First, it is shown that up-regulated miR-24 is correlated with JPH2 
down-regulation in human diseased hearts and that inhibition of miR-24 restores JPH2 
expression in mouse model of cardiac hypertrophy (48). Mechanistic study reveals that 
miR-24 targets and represses JPH2 protein translation through a binding site in the 3’-
terminal of JPH2 mRNA (48). Second, it is reported that JPH2 is the target of miR-34a in 
diseased hearts (173). Third, a very recent study shows that MMP-2 directly cleaves and 
down-regulates JPH2 protein in cardiomyocytes following ischemia/reperfusion injury 
(57). We currently do not know whether these alternative mechanisms are involved in the 
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palmitate-induced down-regulation of JPH2 protein in cardiomyocytes, but it is possible 
that they may contribute to JPH2 protein down-regulation as miR-24, miR-34a and MMP-
2 have been reported to increase in hearts with metabolic disorders (48, 51, 57, 173).    
It is important to point out that the mechanisms mentioned above account for post-
transcriptional and post-translational regulation. The transcription regulatory mechanism 
responsible for JPH2 mRNA expression has never been demonstrated. It is currently 
unknown whether the transcriptional mechanism is involved; however, it merits further 
investigation for calrification. 
4.1.2 Novel cardiac protection of JPH2 against palmitate-induced apoptosis 
JPH2 is an important structural protein in forming junctional membrane complexes (JMCs), 
essential for excitation-contraction coupling within cardiomyocytes (36). It is clear that 
JPH2 is important in anchoring junctional sarcoplasmic reticulum and transverse-tubule 
(T-tubule) membrane invaginations (34). Additionally, JPH2 is also necessary for the 
development of postnatal T-tubules in mammals (174). Recent studies have found that 
JPH2 plays a critical role in maintaining the complex JMC architecture and stabilizing local 
ion channels in mature cardiomyocytes (39). Loss of JPH2’s function by mutations or 
down-regulation of its protein expression is associated with hypertrophic cardiomyopathy, 
arrhythmias, and the progression of heart failure (31, 35, 43). 
The present study reveals an unrecognized role of JPH2 in protecting cardiomyocytes 
against palmitate-induced apoptosis. Several lines of evidences support this conclusion. 
First, a reduction of JPH2 protein is associated with occurrence of apoptosis in 
cardiomyocytes in response to palmitate when compared to oleate. Second, over-
expression of JPH2 attenuates whereas silencing of JPH2 enhances palmitate-induced 
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apoptosis in cardiomyocytes. Third, silencing of JPH2 induces apoptosis in 
cardiomyocytes. This also suggests that JPH2 is necessary for cardiomyocyte survival. 
Thus, this study provides additional evidence in support of cardio-protection by JPH2. Our 
findings together with a previous report (2) suggest that targeting JPH2 may be an effective 
strategy to prevent/treat cardiac injury under stress. 
4.1.3 JPH2 prevention of ER stress in cardiomyocytes during lipotoxicity 
Palmitate has been linked to ER stress contributing to cell death via apoptosis in 
cardiomyocytes (27, 28). In line with this, the present stduy shows that palmitate induces 
CHOP protein expression in cardiomyocytes, indicative of ER stress. Interestingly, the 
induction of CHOP is associated with a reduction of JPH2 in palmitate-stimulated 
cardiomyocytes. Importantly, over-expression of JPH2 prevents palmitate-induced CHOP 
expression in cardiomoycytes. These findings suggest that JPH2 suppresses the induction 
of ER stress in palmitate-stimulated cardiomyocytes. This is further supported by 
additional experimental evidence which shows that silencing of JPH2 induces CHOP 
expression in cardiomoycytes.  
Since our present data has shown that JPH2 protects cardiomyocytes against palmitate-
induced apoptosis, it is reasonable to suspest that the role of JPH2 is mediated through 
prevention of CHOP induction. Indeed, deletion of CHOP attenuates both palmitate- and 
JPH2 knockdown-induced apoptosis in cardiomyocytes. Thus, we argue that palmitate 
leads to a reduction of JPH2, which mediates CHOP induction, leading to apoptosis in 
cardiomyocytes. 
However, we currently do not know the mechanisms by which a reduction of JPH2 induces 
ER stress or CHOP expression in cardiomyocytes. It is well known that ER stress can be 
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caused by oxidative stress, ischemia, disturbance of Ca2+ homeostasis etc. (77, 175-179). 
We know that JPH2 keeps proper Ca2+-induced Ca2+ release in cardiomyocytes. Of note, 
recent studies have demonstrated a role of JPH2 in stabilizing RyR2 (43, 180), which gates 
the release of Ca2+ from ER/SR into the cytosol, suggesting that JPH2 may function as a 
brake on Ca2+ release from RyR2 as the loss of JPH2 results in aberrant Ca2+ leakage from 
the SR through RyR2 (181). Thus, it is most likely that a reduction of JPH2 may lead to 
more Ca2+ release from RyR2 into the cytosol, resulting in an elevation of free Ca2+, which 
contributes to apoptosis in palmitate-stimulated cardiomyocytes. In line with this, we 
shows that palmitate or silencing of JPH2 elevates the levels of free Ca2+ in the cytosol, 
and that over-expression of JPH2 decreases the levels of free Ca2+ in the cytosol in 
palmitate-stimulated cardiomyocytes. Furthermore, blocking Ca2+ release from RyR2 
attenuates CHOP expression and apoptosis induced by palmitate and silencing of JPH2 in 
cardiomyocytes. Nevertheless, it remains to be determined how JPH2 stabilizes RyR2 in 
controlling Ca2+ release in cardiomyocytes. 
On the other hand, an elevation of cytosolic Ca2+ may result from dysfunction of the 
sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) pump and/or Na+-Ca2+ exchanger 
(NCX) as the former pumps Ca2+ into ER/SR and the latter exports Ca2+ outside of 
cardiomyocytes (75). Both are compromised in cardiomyocytes during metabolic disorders 
(181-185). Interestingly, studies have shown that JPH2 regulates NCX participating in 
regulation of Ca2+ homeostasis in cardiomyocytes (181). Future studies are needed to 
determine whether this is also operative in palmitate-stimulated cardiomyocytes.  
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4.1.4 Concluding remarks 
We have provided evidence that demonstartes an unrecognized role of JPH2 in 
cardiomyocytes in prevention of apoptosis induced by palmitate. This new role of JPH2 
may be mediated through attenuation of Ca2+ release from RyR2 and subsequent CHOP 
expression (also see Figure 24). Given that palmitate has been widely used to induce 
lipotoxicity in cardiomyocytes, targeting JPH2 may represent a new therapeutic strategy to 
reduce cardiac injury in lipotoxicity.  
 
 
Figure 24: Summary of findings. 
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4.2 Limitations and future directions 
We used oleate as a control for palmitate. It is better to include the non-treated control and 
investigate whether oleate palys any roles in cardiomyocytes. However, previous studies 
have shown that oleate does not have any effects on apoptosis and junctophilin-2 
expression in cardiomyocytes. 
The present study is focused on isolated neonatal mouse cardiomyocytes. However, the 
role of JPH2 in lipotocixity induced cell injury in vivo remains unknown. High fat diet 
mouse model will be established to investigate whether JPH2 plays a protective role in 
vivo. 
Although our recent study showed that deletion of calpain attenuated the reduction of JPH2 
in palmitate-stimulated cardiomyocytes and mice fed with HFD, we can not exclude other 
mechanisms contributing to JPH2 down-regulation such as through miR-24, miR-34a and 
MMP2, which may be examined in future studies.  
Future studies are also needed to determine how JPH2 modulates Ca2+ release from RyR2 
in cardiomyocytes. Prior studies have shown that JPH2 may be implicated in RyR2 stability. 
Thus, we will investigate the molecular basis of JPH2 stabilizing RyR2 in cardiomyocyets. 
On the other hand, oxidative damage to SERCA may also contribute to cytosolic Ca2+ 
overload in cardiomyocytes (182), which merits further investigation. 
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